Document:

<PAGE>   1
                                                                     EXHIBIT 4.3

                          REGISTRATION RIGHTS AGREEMENT

                                  BY AND AMONG

                               SANMINA CORPORATION

                                   AS ISSUER,

                                       AND

                       MORGAN STANLEY & CO. INCORPORATED,

                                       AND

                         BANC OF AMERICA SECURITIES LLC

                               AS PLACEMENT AGENTS

                            DATED SEPTEMBER 12, 2000

<PAGE>   2

        THIS REGISTRATION RIGHTS AGREEMENT is made and entered into as of
September 12, 2000 by and among Sanmina Corporation, a Delaware corporation (the
"Company"), and Morgan Stanley & Co. Incorporated and Banc of America Securities
LLC pursuant to the Placement Agreement, dated September 6, 2000 (the "Placement
Agreement"), among the Company and the Placement Agents. In order to induce the
Placement Agents to enter into the Placement Agreement, the Company has agreed
to provide the registration rights set forth in this Agreement. The execution of
this Agreement is a condition to the closing under the Placement Agreement.

        The Company agrees with the Placement Agents, (i) for their benefit as
Placement Agents and (ii) for the benefit of the beneficial owners (including
the Placement Agents) from time to time of the Debentures (as defined herein)
and the beneficial owners from time to time of the Underlying Common Stock (as
defined herein) issued upon conversion of the Debentures (each of the foregoing
a "Holder" and together the "Holders"), as follows:

        SECTION 1. DEFINITIONS. Capitalized terms used herein without definition
shall have their respective meanings set forth in the Placement Agreement. As
used in this Agreement, the following terms shall have the following meanings:

        Additional Interest Amount: See Section 2(e) hereof.

        Affiliate: With respect to any specified person, an "affiliate," as
defined in Rule 144, of such person.

        Amendment Effectiveness Deadline Date: See Section 2(d) hereof.

        Applicable Conversion Price: The Applicable Conversion Price as of any
date of determination means the Conversion Price in effect as of such date of
determination or, if no Debentures are then outstanding, the Conversion Price
that would be in effect were Debentures then outstanding.

        Business Day: Each Monday, Tuesday, Wednesday, Thursday and Friday that
is not a day on which banking institutions in The City of New York are
authorized or obligated by law or executive order to close.

        Common Stock: The shares of common stock, par value $0.01 per share, of
the Company and any other shares of common stock as may constitute "Common
Stock" for purposes of the Indenture, including the Underlying Common Stock.

        Conversion Price: Conversion Price shall have the meaning assigned such
term in the Indenture.

        Damages Accrual Period: See Section 2(e) hereof.

        Damages Payment Date: Each September 12 and March 12.

        Debentures: The Zero Coupon Convertible Subordinated Debentures due 2020
of the Company to be purchased pursuant to the Placement Agreement.

<PAGE>   3

        Deferral Notice:  See Section 3(i) hereof.

        Deferral Period:  See Section 3(i) hereof.

        Effectiveness Deadline Date:  See Section 2(a) hereof.

        Effectiveness Period: The period of two years from the later of (a) the
Issue Date and (b) the last date of original issuance of the Debentures, or such
shorter period ending on the date that all Registrable Securities have ceased to
be Registrable Securities.

        Event:  See Section 2(e) hereof.

        Event Date:  See Section 2(e) hereof.

        Event Termination Date:  See Section 2(e) hereof.

        Exchange Act: The Securities Exchange Act of 1934, as amended, and the
rules and regulations of the SEC promulgated thereunder.

        Filing Deadline Date:  See Section 2(a) hereof.

        Holder:  See the second paragraph of this Agreement.

        Indenture: The Indenture, dated as of the date hereof, between the
Company and Norwest Bank Minnesota, N.A., as trustee, pursuant to which the
Debentures are being issued.

        Initial Shelf Registration Statement:  See Section 2(a) hereof.

        Issue Date:  September 12, 2000.

        Losses:  See Section 6 hereof.

        Material Event:  See Section 3(i) hereof.

        Notice and Questionnaire: A written notice delivered to the Company
containing substantially the information called for by the Selling
Securityholder Notice and Questionnaire attached as Annex A to the Offering
Memorandum of the Company issued September 6, 2000 relating to the Debentures.

        Notice Holder: On any date, any Holder that has delivered an
appropriately completed Notice and Questionnaire to the Company on or prior to
such date.

        Placement Agents: Morgan Stanley & Co. Incorporated and Banc of America
Securities LLC.

        Placement Agreement: See the preamble hereof.

        Prospectus: The prospectus included in any Registration Statement
(including, without limitation, a prospectus that discloses information
previously omitted from a prospectus filed as

                                       3
<PAGE>   4

part of an effective registration statement in reliance upon Rule 430A
promulgated under the Securities Act), as amended or supplemented by any
amendment or prospectus supplement, including post-effective amendments, and all
materials incorporated by reference or explicitly deemed to be incorporated by
reference in such Prospectus.

        Record Holder: (i) With respect to any Damages Payment Date relating to
any Debentures as to which any such Additional Interest Amount has accrued, the
holder of record of such Debenture on the record date fifteen (15) days prior to
such Damages Payment Date and (ii) with respect to any Damages Payment Date
relating to the Underlying Common Stock as to which any such Additional Interest
Amount has accrued, the registered holder of such Underlying Common Stock
fifteen (15) days prior to such Damages Payment Date.

        Registrable Securities: The Debentures until such Debentures have been
converted or exchanged into the Underlying Common Stock and, at all times
subsequent to any such conversion or exchange the Underlying Securities and any
securities into or for which such Underlying Common Stock have been converted or
exchanged, and any security issued with respect thereto upon any stock dividend,
split or similar event until, in the case of any such security, (A) the earliest
of (i) its effective registration under the Securities Act and resale in
accordance with the Registration Statement covering it, (ii) expiration of the
holding period that would be applicable thereto under Rule 144(k) were it not
held by an Affiliate of the Company or (iii) its sale to the public pursuant to
Rule 144, and (B) as a result of the event or circumstance described in any of
the foregoing clauses (i) through (iii), the legends with respect to transfer
restrictions required under the Indenture are removed or removable in accordance
with the terms of the Indenture or such legends, as the case may be.

        Registration Expenses:  See Section 5 hereof.

        Registration Statement: Any registration statement of the Company that
covers any of the Registrable Securities pursuant to the provisions of this
Agreement including the Prospectus, amendments and supplements to such
registration statement, including post-effective amendments, all exhibits, and
all materials incorporated by reference or explicitly deemed to be incorporated
by reference in such registration statement.

        Restated Principal Amount:  As this term is defined in the Indenture.

        Restricted Securities:  As this term is defined in Rule 144.

        Rule 144: Rule 144 under the Securities Act, as such Rule may be amended
from time to time, or any similar rule or regulation hereafter adopted by the
SEC.

        Rule 144A: Rule 144A under the Securities Act, as such Rule may be
amended from time to time, or any similar rule or regulation hereafter adopted
by the SEC.

        SEC:  The Securities and Exchange Commission.

        Securities Act: The Securities Act of 1933, as amended, and the rules
and regulations promulgated by the SEC thereunder.

                                       4
<PAGE>   5

        Shelf Registration Statement:  See Section 2(a) hereof.

        Subsequent Shelf Registration Statement:  See Section 2(b) hereof.

        Tax Event:  As this term is defined in the Indenture.

        TIA:  The Trust Indenture Act of 1939, as amended.

        Trustee: Norwest Bank Minnesota, N.A. (or any successor entity), the
Trustee under the Indenture.

        Underlying Common Stock: The Common Stock into which the Debentures are
convertible or issued upon any such conversion.

        SECTION 2. SHELF REGISTRATION.

            (a) The Company shall prepare and file or cause to be prepared and
filed with the SEC, as soon as practicable but in any event by the date (the
"Filing Deadline Date") ninety (90) days after the Issue Date, a Registration
Statement for an offering to be made on a delayed or continuous basis pursuant
to Rule 415 of the Securities Act (a "Shelf Registration Statement") registering
the resale from time to time by Holders thereof of all of the Registrable
Securities (the "Initial Shelf Registration Statement"). The Initial Shelf
Registration Statement shall be on Form S-3 or another appropriate form
permitting registration of such Registrable Securities for resale by such
Holders in accordance with the methods of distribution elected by the Holders
and set forth in the Initial Shelf Registration Statement. The Company shall use
its reasonable efforts to cause the Initial Shelf Registration Statement to be
declared effective under the Securities Act as promptly as is practicable but in
any event by the date (the "Effectiveness Deadline Date") that is one hundred
eighty (180) days after the Issue Date, and to keep the Initial Shelf
Registration Statement (or any Subsequent Shelf Registration Statement)
continuously effective under the Securities Act until the expiration of the
Effectiveness Period. At the time the Initial Shelf Registration Statement is
declared effective, each Holder that became a Notice Holder on or prior to the
date ten (10) Business Days prior to such time of effectiveness shall be named
as a selling securityholder in the Initial Shelf Registration Statement and the
related Prospectus in such a manner as to permit such Holder to deliver such
Prospectus to purchasers of Registrable Securities in accordance with applicable
law. None of the Company's security holders (other than the Holders of
Registrable Securities) shall have the right to include any of the Company's
securities in the Shelf Registration Statement.

            (b) If the Initial Shelf Registration Statement or any Subsequent
Shelf Registration Statement ceases to be effective for any reason at any time
during the Effectiveness Period (other than because all Registrable Securities
registered thereunder shall have been resold pursuant thereto or shall have
otherwise ceased to be Registrable Securities), the Company shall use its
reasonable efforts to obtain the prompt withdrawal of any order suspending the
effectiveness thereof, and in any event shall within thirty (30) days of such
cessation of effectiveness amend the Shelf Registration Statement in a manner
reasonably expected to obtain the withdrawal of the order suspending the
effectiveness thereof, or file an additional Shelf Registration Statement
covering all of the securities that as of the date of such filing are
Registrable Securities (a "Subsequent Shelf Registration Statement"). If a
Subsequent Shelf

                                       5
<PAGE>   6

Registration Statement is filed, the Company shall use reasonable efforts to
cause the Subsequent Shelf Registration Statement to become effective as
promptly as is practicable after such filing and to keep such Registration
Statement (or subsequent Shelf Registration Statement) continuously effective
until the end of the Effectiveness Period.

            (c) The Company shall supplement and amend the Shelf Registration
Statement if required by the rules, regulations or instructions applicable to
the registration form used by the Company for such Shelf Registration Statement,
if required by the Securities Act or as reasonably requested by the Placement
Agents or by the Trustee on behalf of the registered Holders or by any managing
underwriter in the event of an underwritten offering.

            (d) Each Holder of Registrable Securities agrees that if such Holder
wishes to sell Registrable Securities pursuant to a Shelf Registration Statement
and related Prospectus, it will do so only in accordance with this Section 2(d)
and Section 3(i). Each Holder of Registrable Securities wishing to sell
Registrable Securities pursuant to a Shelf Registration Statement and related
Prospectus agrees to deliver a Notice and Questionnaire to the Company at least
three (3) Business Days prior to any intended distribution of Registrable
Securities under the Shelf Registration Statement. From and after the date the
Initial Shelf Registration Statement is declared effective, the Company shall,
as promptly as practicable after the date a Notice and Questionnaire is
delivered, and in any event upon the later of (x) five (5) Business Days after
such date or (y) five (5) Business Days after the expiration of any Deferral
Period in effect when the Notice and Questionnaire is delivered or put into
effect within five (5) Business Days of such delivery date, (i) if required by
applicable law, file with the SEC a post-effective amendment to the Shelf
Registration Statement or prepare and, if required by applicable law, file a
supplement to the related Prospectus or a supplement or amendment to any
document incorporated therein by reference or file any other required document
so that the Holder delivering such Notice and Questionnaire is named as a
selling securityholder in the Shelf Registration Statement and the related
Prospectus in such a manner as to permit such Holder to deliver such Prospectus
to purchasers of the Registrable Securities in accordance with applicable law
and, if the Company shall file a post-effective amendment to the Shelf
Registration Statement, use reasonable efforts to cause such post-effective
amendment to be declared effective under the Securities Act as promptly as is
practicable, but in any event by the date (the "Amendment Effectiveness Deadline
Date") that is forty-five (45) days after the date such post-effective amendment
is required by this clause to be filed; (ii) provide such Holder copies of any
documents filed pursuant to Section 2(d)(i); and (iii) notify such Holder as
promptly as practicable after the effectiveness under the Securities Act of any
post-effective amendment filed pursuant to Section 2(d)(i); provided, that if
such Notice and Questionnaire is delivered during a Deferral Period, the Company
shall so inform the Holder delivering such Notice and Questionnaire and shall
take the actions set forth in clauses (i), (ii) and (iii) above upon expiration
of the Deferral Period in accordance with Section 3(i). Notwithstanding anything
contained herein to the contrary, (i) the Company shall be under no obligation
to name any Holder that is not a Notice Holder as a selling securityholder in
any Registration Statement or related Prospectus and (ii) the Amendment Deadline
Effective Date shall be extended by up to ten (10) Business Days from the
expiration of a Deferral Period (and the Company shall incur no obligation to
pay Additional Interest during such extension) if such Deferral Period shall be
in effect on the Amendment Deadline Effective Date.

                                       6
<PAGE>   7

            (e) The parties hereto agree that the Holders of Registrable
Securities will suffer damages, and that it would not be feasible to ascertain
the extent of such damages with precision, if (i) the Initial Shelf Registration
Statement has not been filed on or prior to the Filing Deadline Date, (ii) the
Initial Shelf Registration Statement has not been declared effective under the
Securities Act on or prior to the Effectiveness Deadline Date, (iii) the Company
has failed to perform its obligations set forth in Section 2(d) within the time
period required therein, (iv) the aggregate duration of Deferral Periods in any
period exceeds the number of days permitted in respect of such period pursuant
to Section 3(i) hereof or (v) the number of Deferral Periods in any period
exceeds the number permitted in respect of such period pursuant to Section 3(i)
hereof (each of the events of a type described in any of the foregoing clauses
(i) through (v) are individually referred to herein as an "Event," and the
Filing Deadline Date in the case of clause (i), the Effectiveness Deadline Date
in the case of clause (ii), the date by which the Company is required to perform
its obligations set forth in Section 2(d) in the case of clause (iii) (including
the filing of any post-effective amendment prior to the Amendment Effectiveness
Deadline Date), the date on which the aggregate duration of Deferral Periods in
any period exceeds the number of days permitted by Section 3(i) hereof in the
case of clause (iv), and the date of the commencement of a Deferral Period that
causes the limit on the number of Deferral Periods in any period under Section
3(i) hereof to be exceeded in the case of clause (v), being referred to herein
as an "Event Date"). Events shall be deemed to continue until the "Event
Termination Date," which shall be the following dates with respect to the
respective types of Events: the date the Initial Shelf Registration Statement is
filed in the case of an Event of the type described in clause (i), the date the
Initial Shelf Registration Statement is declared effective under the Securities
Act in the case of an Event of the type described in clause (ii), the date the
Company performs its obligations set forth in Section 2(d) in the case of an
Event of the type described in clause (iii) (including, without limitation, the
date the relevant post-effective amendment to the Shelf Registration Statement
is declared effective under the Securities Act), termination of the Deferral
Period that caused the limit on the aggregate duration of Deferral Periods in a
period set forth in Section 3(i) to be exceeded in the case of the commencement
of an Event of the type described in clause (iv), and termination of the
Deferral Period the commencement of which caused the number of Deferral Periods
in a period permitted by Section 3(i) to be exceeded in the case of an Event of
the type described in clause (v).

        Accordingly, commencing on (and including) any Event Date and ending on
(but excluding) the next date on which there are no Events that have occurred
and are continuing (a "Damages Accrual Period"), the Company agrees to pay, as
additional interest and not as a penalty, an amount (the "Additional Interest
Amount"), payable on the Damages Payment Dates to Record Holders of Debentures
that are Registrable Securities and of shares of Underlying Common Stock issued
upon conversion of Debentures that are Registrable Securities, as the case may
be, accruing, for each portion of such Damages Accrual Period beginning on and
including a Damages Payment Date (or, in respect of the first time that the
Additional Interest Amount is to be paid to Holders on a Damages Payment Date as
a result of the occurrence of any particular Event, from the Event Date) and
ending on but excluding the first to occur of (A) the date of the end of the
Damages Accrual Period or (B) the next Damages Payment Date, at a rate per annum
equal to one-half of one percent (0.5 %) of the principal amount at maturity of
such Debentures (or, following a Tax Event, of the Restated Principal Amount
plus accrued but unpaid interest) or one-half of one percent (0.5 %) of the
Applicable Conversion Price of such shares of Underlying Common Stock, as the
case may be, in each case determined as of the Business Day immediately

                                       7
<PAGE>   8

preceding the next Damages Payment Date; provided, that in the case of a Damages
Accrual Period that is in effect solely as a result of an Event of the type
described in clause (iii) of the immediately preceding paragraph, such
Additional Interest Amount shall be paid only to the Holders that have delivered
Notice and Questionnaires that caused the Company to incur the obligations set
forth in Section 2(d) the non-performance of which is the basis of such Event,
provided further, that any Additional Interest Amount accrued with respect to
any Debenture or portion thereof called for redemption on a redemption date or
converted into Underlying Common Stock on a conversion date prior to the Damages
Payment Date, shall, in any such event, be paid instead to the Holder who
submitted such Debenture or portion thereof for redemption or conversion on the
applicable redemption date or conversion date, as the case may be, on such date
(or promptly following the conversion date, in the case of conversion).
Notwithstanding the foregoing, no Additional Interest Amounts shall accrue as to
any Registrable Security from and after the earlier of (x) the date such
security is no longer a Registrable Security and (y) expiration of the
Effectiveness Period. The rate of accrual of the Additional Interest Amount with
respect to any period shall not exceed the rate provided for in this paragraph
notwithstanding the occurrence of multiple concurrent Events. Following the cure
of all Events requiring the payment by the Company of Additional Interest
Amounts to the Holders of Registrable Securities pursuant to this Section, the
accrual of Additional Interest Amounts will cease (without in any way limiting
the effect of any subsequent Event requiring the payment of Additional Interest
Amount by the Company).

        The Trustee shall be entitled, on behalf of Holders of Debentures or
Underlying Common Stock, to seek any available remedy for the enforcement of
this Agreement, including for the payment of any Additional Interest Amount.
Notwithstanding the foregoing, the parties agree that the sole damages payable
for a violation of the terms of this Agreement with respect to which Additional
Interest are expressly provided shall be such Additional Interest. Nothing shall
preclude a Notice Holder or Holder of Registrable Securities from pursuing or
obtaining specific performance or other equitable relief with respect to this
Agreement.

        All of the Company's obligations set forth in this Section 2(e) that are
outstanding with respect to any Registrable Security at the time such security
ceases to be a Registrable Security shall survive until such time as all such
obligations with respect to such security have been satisfied in full
(notwithstanding termination of this Agreement pursuant to Section 8(k)).

        The parties hereto agree that the Additional Interest provided for in
this Section 2(e) constitute a reasonable estimate of the damages that may be
incurred by Holders of Registrable Securities by reason of the failure of the
Shelf Registration Statement to be filed or declared effective or available for
effecting resales of Registrable Securities in accordance with the provisions
hereof.

        SECTION 3. REGISTRATION PROCEDURES. In connection with the registration
obligations of the Company under Section 2 hereof, the Company shall:

            (a) Before filing any Registration Statement or Prospectus or any
amendments or supplements thereto with the SEC, furnish to counsel to the
Placement Agents copies of all such documents proposed to be filed and use
reasonable efforts to reflect in each such document

                                       8
<PAGE>   9

when so filed with the SEC such comments as counsel to the Placement Agents
reasonably shall propose within five (5) Business Days of the delivery of such
copies to the Placement Agents.

            (b) Prepare and file with the SEC such amendments and post-effective
amendments to each Registration Statement as may be necessary to keep such
Registration Statement continuously effective for the applicable period
specified in Section 2(a); cause the related Prospectus to be supplemented by
any required Prospectus supplement, and as so supplemented to be filed pursuant
to Rule 424 (or any similar provisions then in force) under the Securities Act;
and use its reasonable efforts to comply with the provisions of the Securities
Act applicable to it with respect to the disposition of all securities covered
by such Registration Statement during the Effectiveness Period in accordance
with the intended methods of disposition by the sellers thereof set forth in
such Registration Statement as so amended or such Prospectus as so supplemented.

            (c) As promptly as practicable give notice to counsel to the Notice
Holders and the Placement Agents (i) when any Prospectus, Prospectus supplement,
Registration Statement or post-effective amendment to a Registration Statement
has been filed with the SEC and, with respect to a Registration Statement or any
post-effective amendment, when the same has been declared effective, (ii) of any
request, following the effectiveness of the Initial Shelf Registration Statement
under the Securities Act, by the SEC or any other federal or state governmental
authority for amendments or supplements to any Registration Statement or related
Prospectus or for additional information, (iii) of the issuance by the SEC or
any other federal or state governmental authority of any stop order suspending
the effectiveness of any Registration Statement or the initiation or threatening
of any proceedings for that purpose, (iv) of the receipt by the Company of any
notification with respect to the suspension of the qualification or exemption
from qualification of any of the Registrable Securities for sale in any
jurisdiction or the initiation or threatening of any proceeding for such
purpose, (v) of the occurrence of (but not the nature of or details concerning)
a Material Event and (vi) of the determination by the Company that a
post-effective amendment to a Registration Statement will be filed with the SEC,
which notice may, at the discretion of the Company (or as required pursuant to
Section 3(i)), state that it constitutes a Deferral Notice, in which event the
provisions of Section 3(i) shall apply.

            (d) Use reasonable efforts to obtain the withdrawal of any order
suspending the effectiveness of a Registration Statement or the lifting of any
suspension of the qualification (or exemption from qualification) of any of the
Registrable Securities for sale in any jurisdiction in which they have been
qualified for sale, in either case at the earliest possible moment.

            (e) If reasonably requested by the Placement Agents or any Notice
Holder, as promptly as practicable incorporate in a Prospectus supplement or
post-effective amendment to a Registration Statement such information as the
Placement Agents or such Notice Holder shall, on the basis of a written opinion
of nationally-recognized counsel experienced in such matters, determine to be
required to be included therein by applicable law and make any required filings
of such Prospectus supplement or such post-effective amendment.

            (f) As promptly as practicable furnish to each Notice Holder and the
Placement Agents, without charge, at least one (1) conformed copy of the
Registration Statement

                                       9
<PAGE>   10

and any amendment thereto, including financial statements but excluding
schedules, all documents incorporated or deemed to be incorporated therein by
reference and all exhibits (unless requested in writing to the Company by such
Notice Holder or the Placement Agents, as the case may be).

            (g) During the Effectiveness Period, deliver to each Notice Holder
in connection with any sale of Registrable Securities pursuant to a Registration
Statement, without charge, as many copies of the Prospectus or Prospectuses
relating to such Registrable Securities (including each preliminary prospectus)
and any amendment or supplement thereto as such Notice Holder may reasonably
request; and the Company hereby consents (except during such periods that a
Deferral Notice is outstanding and has not been revoked) to the use of such
Prospectus or each amendment or supplement thereto by each Notice Holder in
connection with any offering and sale of the Registrable Securities covered by
such Prospectus or any amendment or supplement thereto in the manner set forth
therein.

            (h) Prior to any public offering of the Registrable Securities
pursuant to the Shelf Registration Statement, register or qualify or cooperate
with the Notice Holders in connection with the registration or qualification (or
exemption from such registration or qualification) of such Registrable
Securities for offer and sale under the securities or Blue Sky laws of such
jurisdictions within the United States as any Notice Holder reasonably requests
in writing (which request may be included in the Notice and Questionnaire);
prior to any public offering of the Registrable Securities pursuant to the Shelf
Registration Statement, keep each such registration or qualification (or
exemption therefrom) effective during the Effectiveness Period in connection
with such Notice Holder's offer and sale of Registrable Securities pursuant to
such registration or qualification (or exemption therefrom) and do any and all
other acts or things necessary or advisable to enable the disposition in such
jurisdictions of such Registrable Securities in the manner set forth in the
relevant Registration Statement and the related Prospectus; provided, that the
Company will not be required to (i) qualify as a foreign corporation or as a
dealer in securities in any jurisdiction where it would not otherwise be
required to qualify but for this Agreement or (ii) take any action that would
subject it to general service of process in suits or to taxation in any such
jurisdiction where it is not then so subject.

            (i) Upon (A) the issuance by the SEC of a stop order suspending the
effectiveness of the Shelf Registration Statement or the initiation of
proceedings with respect to the Shelf Registration Statement under Section 8(d)
or 8(e) of the Securities Act, (B) the occurrence of any event or the existence
of any fact (a "Material Event") as a result of which any Registration Statement
shall contain any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary to make the statements
therein not misleading, or any Prospectus shall contain any untrue statement of
a material fact or omit to state any material fact required to be stated therein
or necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading, or (C) the occurrence or existence
of any pending corporate development that, in the reasonable discretion of the
Company, makes it appropriate to suspend the availability of the Shelf
Registration Statement and the related Prospectus, (i) in the case of clause (B)
above, subject to the next sentence, as promptly as practicable prepare and
file, if necessary pursuant to applicable law, a post-effective amendment to
such Registration Statement or a supplement to the related Prospectus or any
document incorporated therein by reference or file any other required

                                       10
<PAGE>   11

document that would be incorporated by reference into such Registration
Statement and Prospectus so that such Registration Statement does not contain
any untrue statement of a material fact or omit to state any material fact
required to be stated therein or necessary to make the statements therein not
misleading, and such Prospectus does not contain any untrue statement of a
material fact or omit to state any material fact required to be stated therein
or necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading, as thereafter delivered to the
purchasers of the Registrable Securities being sold thereunder, and, in the case
of a post-effective amendment to a Registration Statement, subject to the next
sentence, use its reasonable efforts to cause it to be declared effective as
promptly as is practicable, and (ii) give notice to the Notice Holders that the
availability of the Shelf Registration Statement is suspended (a "Deferral
Notice") and, upon receipt of any Deferral Notice, each Notice Holder agrees not
to sell any Registrable Securities pursuant to the Registration Statement until
such Notice Holder's receipt of copies of the supplemented or amended Prospectus
provided for in clause (i) above, or until it is advised in writing by the
Company that the Prospectus may be used, and has received copies of any
additional or supplemental filings that are incorporated or deemed incorporated
by reference in such Prospectus. The Company will use all reasonable efforts to
ensure that the use of the Prospectus may be resumed (x) in the case of clause
(A) above, as promptly as is practicable, (y) in the case of clause (B) above,
as soon as, in the sole judgment of the Company, public disclosure of such
Material Event would not be prejudicial to or contrary to the interests of the
Company or, if necessary to avoid unreasonable burden or expense, as soon as
practicable thereafter and (z) in the case of clause (C) above, as soon as, in
the discretion of the Company, such suspension is no longer appropriate. The
Company shall be entitled to exercise its right under this Section 3(i) to
suspend the availability of the Shelf Registration Statement or any Prospectus,
without incurring or accruing any obligation to pay Additional Interest pursuant
to Section 2(e), no more than one (1) time in any three month period or four (4)
times in any twelve month period, and any such period during which the
availability of the Registration Statement and any Prospectus is suspended (the
"Deferral Period") shall, without incurring any obligation to pay Additional
Interest pursuant to Section 2(e), not exceed 30 days; provided, that in the
case of a Material Event relating to an acquisition or a probable acquisition or
financing, recapitalization, business combination or other similar transaction,
the Company may, without incurring any obligation to pay Additional Interest
pursuant to Section 2(e), deliver to Notice Holders a second notice to the
effect set forth above, which shall have the effect of extending the Deferral
Period by up to an additional 30 days, or such shorter period of time as is
specified in such second notice, provided, that the aggregate duration of any
Deferral Periods shall not, without incurring any obligation to pay Additional
Interest pursuant to Section 2(e), exceed 60 days in any three month period or
90 days in any twelve (12) month period.

            (j) If requested in writing in connection with a disposition of
Registrable Securities pursuant to a Registration Statement, make reasonably
available for inspection during normal business hours by a representative for
the Notice Holders of such Registrable Securities and any broker-dealers,
attorneys and accountants retained by such Notice Holders, all relevant
financial and other records, pertinent corporate documents and properties of the
Company and its subsidiaries, and cause the appropriate officers, directors and
employees of the Company and its subsidiaries to make reasonably available for
inspection during normal business hours on reasonable notice all relevant
information reasonably requested by such representative for the Notice Holders
or any such broker-dealers, attorneys or accountants in connection with such

                                       11
<PAGE>   12

disposition, in each case as is customary for similar "due diligence"
examinations; provided, however, that such persons shall first agree in writing
with the Company that any information that is reasonably and in good faith
designated by the Company in writing as confidential at the time of delivery of
such information shall be kept confidential by such persons and shall be used
solely for the purposes of exercising rights under this Agreement, unless (i)
disclosure of such information is required by court or administrative order or
is necessary to respond to inquiries of regulatory authorities, (ii) disclosure
of such information is required by law (including any disclosure requirements
pursuant to federal securities laws in connection with the filing of any
Registration Statement or the use of any Prospectus referred to in this
Agreement), (iii) such information becomes generally available to the public
other than as a result of a disclosure or failure to safeguard by any such
person or (iv) such information becomes available to any such person from a
source other than the Company and such source is not bound by a confidentiality
agreement, and provided further, that the foregoing inspection and information
gathering shall, to the greatest extent possible, be coordinated on behalf of
all the Notice Holders and the other parties entitled thereto by the counsel
referred to in Section 5.

            (k) Use all reasonable efforts to comply with all applicable rules
and regulations of the SEC and make generally available to its securityholders
earning statements (which need not be audited) satisfying the provisions of
Section 11(a) of the Securities Act and Rule 158 thereunder (or any similar rule
promulgated under the Securities Act) no later than 45 days after the end of any
3-month period (or 90 days after the end of any 12-month period if such period
is a fiscal year) commencing on the first day of the first fiscal quarter of the
Company commencing after the effective date of a Registration Statement, which
statements shall cover said periods.

            (l) Cooperate with each Notice Holder to facilitate the timely
preparation and delivery of certificates representing Registrable Securities
sold or to be sold pursuant to a Registration Statement, which certificates
shall not bear any restrictive legends, and cause such Registrable Securities to
be in such denominations as are permitted by the indenture and registered in
such names as such Notice Holder may request in writing at least two (2)
Business Days prior to any sale of such Registrable Securities.

            (m) Provide a CUSIP number for all Registrable Securities covered by
each Registration Statement not later than the effective date of such
Registration Statement and provide the Trustee and the transfer agent for the
Common Stock with printed certificates for the Registrable Securities that are
in a form eligible for deposit with The Depository Trust Company.

            (n) Provide such information as is required for any filings required
to be made with the National Association of Securities Dealers, Inc.

            (o) Upon (i) the filing of the Initial Registration Statement and
(ii) the effectiveness of the Initial Registration Statement, announce the same,
in each case by release to Reuters Economic Services and Bloomberg Business
News.

        SECTION 4. HOLDER'S OBLIGATIONS. Each Holder agrees, by acquisition of
the Registrable Securities, that no Holder of Registrable Securities shall be
entitled to sell any of such Registrable Securities pursuant to a Registration
Statement or to receive a Prospectus

                                       12
<PAGE>   13

relating thereto, unless such Holder has furnished the Company with a Notice and
Questionnaire as required pursuant to Section 2(d) hereof (including the
information required to be included in such Notice and Questionnaire) and the
information set forth in the next sentence. Each Notice Holder agrees promptly
to furnish to the Company all information required to be disclosed in order to
make the information previously furnished to the Company by such Notice Holder
not misleading and any other information regarding such Notice Holder and the
distribution of such Registrable Securities as the Company may from time to time
reasonably request. Any sale of any Registrable Securities by any Holder shall
constitute a representation and warranty by such Holder that the information
relating to such Holder and its plan of distribution is as set forth in the
Prospectus delivered by such Holder in connection with such disposition, that
such Prospectus does not as of the time of such sale contain any untrue
statement of a material fact relating to or provided by such Holder or its plan
of distribution and that such Prospectus does not as of the time of such sale
omit to state any material fact relating to or provided by such Holder or its
plan of distribution necessary to make the statements in such Prospectus, in the
light of the circumstances under which they were made, not misleading.

        SECTION 5. REGISTRATION EXPENSES. The Company shall bear all fees and
expenses incurred in connection with the performance by the Company of its
obligations under Sections 2 and 3 of this Agreement whether or not any of the
Registration Statements are declared effective. Such fees and expenses shall
include, without limitation, (i) all registration and filing fees (including,
without limitation, fees and expenses (x) with respect to filings required to be
made with the National Association of Securities Dealers, Inc. and (y) of
compliance with federal and state securities or Blue Sky laws (including,
without limitation, reasonable fees and disbursements of the counsel specified
in the next sentence in connection with Blue Sky qualifications of the
Registrable Securities under the laws of such jurisdictions as the Notice
Holders of a majority of the Registrable Securities being sold pursuant to a
Registration Statement may designate), (ii) printing expenses (including,
without limitation, expenses of printing certificates for Registrable Securities
in a form eligible for deposit with The Depository Trust Company), (iii)
duplication expenses relating to copies of any Registration Statement or
Prospectus delivered to any Holders hereunder, (iv) fees and disbursements of
counsel for the Company in connection with the Shelf Registration Statement, (v)
reasonable fees and disbursements of the Trustee and its counsel and of the
registrar and transfer agent for the Common Stock and (vi) Securities Act
liability insurance obtained by the Company in its sole discretion. In addition,
the Company shall bear or reimburse the Notice Holders for the reasonable fees
and disbursements of one firm of legal counsel for the Holders, which shall
initially be Simpson Thacher & Bartlett, but which may, with the written consent
of the Placement Agents (which shall not be unreasonably withheld), be another
nationally recognized law firm experienced in securities law matters designated
by the Company. In addition, the Company shall pay the internal expenses of the
Company (including, without limitation, all salaries and expenses of officers
and employees performing legal or accounting duties), the expense of any annual
audit, the fees and expenses incurred in connection with the listing of the
Registrable Securities on any securities exchange on which similar securities of
the Company are then listed and the fees and expenses of any person, including
special experts, retained by the Company. Notwithstanding the provisions of this
Section 5, each seller of Registrable Securities shall pay selling expenses and
all registration expenses to the extent required by applicable law.

                                       13
<PAGE>   14

        SECTION 6. INDEMNIFICATION.

            (a) Indemnification by the Company. The Company shall indemnify and
hold harmless each Notice Holder and each person, if any, who controls any
Notice Holder (within the meaning of either Section 15 of the Securities Act or
Section 20 of the Exchange Act) from and against any losses, liabilities,
claims, damages and expenses (including, without limitation, any legal or other
expenses reasonably incurred in connection with defending or investigating any
such action or claim) (collectively, "Losses"), arising out of or based upon any
untrue statement or alleged untrue statement of a material fact contained in any
Registration Statement or Prospectus or in any amendment or supplement thereto
or in any preliminary prospectus, or arising out of or based upon any omission
or alleged omission to state therein a material fact required to be stated
therein or necessary to make the statements therein not misleading, provided,
however, that the Company shall not be liable in any such case to the extent
that any such Losses arise out of or are based upon an untrue statement or
alleged untrue statement contained in or omission or alleged omission from any
of such documents in reliance upon and conformity with any of the information
relating to the Holders furnished to the Company in writing by a Holder
expressly for use therein; provided further, that the indemnification contained
in this paragraph shall not inure to the benefit of any Holder of Registrable
Securities (or to the benefit of any person controlling such Holder) on account
of any such Losses arising out of or based upon an untrue statement or alleged
untrue statement or omission or alleged omission made in any preliminary
prospectus provided in each case the Company has performed its obligations under
Section 3(a) hereof if either (A) (i) such Holder failed to send or deliver a
copy of the Prospectus with or prior to the delivery of written confirmation of
the sale by such Holder to the person asserting the claim from which such Losses
arise and (ii) the Prospectus would have corrected such untrue statement or
alleged untrue statement or such omission or alleged omission, or (B) (x) such
untrue statement or alleged untrue statement, omission or alleged omission is
corrected in an amendment or supplement to the Prospectus and (y) having
previously been furnished by or on behalf of the Company with copies of the
Prospectus as so amended or supplemented, such Holder thereafter fails to
deliver such Prospectus as so amended or supplemented, with or prior to the
delivery of written confirmation of the sale of a Registrable Security to the
person asserting the claim from which such Losses arise.

            (b) Indemnification by Holders of Registrable Securities. Each
Holder agrees severally and not jointly to indemnify and hold harmless the
Company and its respective directors and officers, and each person, if any, who
controls the Company (within the meaning of either Section 15 of the Securities
Act or Section 20 of the Exchange Act) or any other Holder, from and against all
Losses arising out of or based upon any untrue statement or alleged untrue
statement of a material fact contained in any Registration Statement or
Prospectus or in any amendment or supplement thereto or in any preliminary
prospectus, or arising out of or based upon any omission or alleged omission to
state therein a material fact required to be stated therein or necessary to make
the statements therein not misleading, to the extent, but only to the extent,
that such untrue statement or alleged untrue statement or omission or alleged
omission was made in reliance upon and in conformity with information furnished
to the Company by such Holder expressly for use in such Registration Statement
or Prospectus or amendment or supplement thereto. In no event shall the
liability of any selling Holder of Registrable Securities hereunder be greater
in amount than the dollar amount of the proceeds received by such Holder

                                       14
<PAGE>   15

upon the sale of the Registrable Securities pursuant to the Registration
Statement giving rise to such indemnification obligation.

            (c) Conduct of Indemnification Proceedings. In case any proceeding
(including any governmental investigation) shall be instituted involving any
person in respect of which indemnity may be sought pursuant to either of the two
preceding paragraphs, such person (the "indemnified party") shall promptly
notify the person against whom such indemnity may be sought (the "indemnifying
party") in writing and the indemnifying party, upon request of the indemnified
party, shall retain counsel reasonably satisfactory to the indemnified party to
represent the indemnified party and any others the indemnifying party may
designate in such proceeding and shall pay the reasonable fees and disbursements
of such counsel related to such proceeding. In any such proceeding, any
indemnified party shall have the right to retain its own counsel, but the fees
and expenses of such counsel shall be at the expense of such indemnified party
unless (i) the indemnifying party and the indemnified party shall have mutually
agreed to the retention of such counsel or (ii) the named parties to any such
proceeding (including any impleaded parties) include both the indemnifying party
and the indemnified party and representation of both parties by the same counsel
would be inappropriate due to actual or potential differing interests between
them. It is understood that the indemnifying party shall not, in respect of the
legal expenses of any indemnified party in connection with any proceeding or
related proceedings in the same jurisdiction, be liable for the fees and
expenses of more than one separate firm (in addition to any local counsel) for
all indemnified parties, and that all such fees and expenses shall be reimbursed
as they are incurred. Such separate firm shall be designated in writing by, in
the case of parties indemnified pursuant to Section 6(a), the Holders of a
majority (with Holders of Debentures deemed to be the Holders, for purposes of
determining such majority, of the number of shares of Underlying Common Stock
into which such Debentures are or would be convertible or exchangeable as of the
date on which such designation is made) of the Registrable Securities covered by
the Registration Statement held by Holders that are indemnified parties pursuant
to Section 6(a) and, in the case of parties indemnified pursuant to Section
6(b), the Company. The indemnifying party shall not be liable for any settlement
of any proceeding effected without its written consent, but if settled with such
consent or if there be a final judgment for the plaintiff, the indemnifying
party agrees to indemnify the indemnified party from and against any loss or
liability by reason of such settlement or judgment. Notwithstanding the
foregoing sentence, if at any time an indemnified party shall have requested an
indemnifying party to reimburse the indemnified party for fees and expenses of
counsel and the indemnified party would be entitled thereto pursuant to the
second and third sentences of this paragraph, the indemnifying party agrees that
it shall be liable for any settlement of any proceeding effected without its
written consent if (i) such settlement is entered into more than 45 days after
receipt by such indemnifying party of the aforesaid request and (ii) such
indemnifying party shall not have reimbursed the indemnified party in accordance
with such request prior to the date of such settlement. No indemnifying party
shall, without the prior written consent of the indemnified party, effect any
settlement of any pending or threatened proceeding in respect of which any
indemnified party is or could have been a party and indemnity could have been
sought hereunder by such indemnified party, unless such settlement includes an
unconditional release of such indemnified party from all liability on claims
that are the subject matter of such proceeding.

            (d) Contribution. To the extent that the indemnification provided
for in this Section 6 is unavailable to an indemnified party under Section 6(a)
or 6(b) hereof in respect of

                                       15
<PAGE>   16

any Losses or is insufficient to hold such indemnified party harmless, then each
applicable indemnifying party, in lieu of indemnifying such indemnified party,
shall contribute to the amount paid or payable by such indemnified party as a
result of such Losses (i) in such proportion as is appropriate to reflect the
relative benefits received by the indemnifying party or parties on the one hand
and the indemnified party or parties on the other hand or (ii) if the allocation
provided by clause (i) above is not permitted by applicable law, in such
proportion as is appropriate to reflect not only the relative benefits referred
to in clause (i) above but also the relative fault of the indemnifying party or
parties on the one hand and of the indemnified party or parties on the other
hand in connection with the statements or omissions that resulted in such
Losses, as well as any other relevant equitable considerations. Benefits
received by the Company shall be deemed to be equal to the total net proceeds
from the initial placement pursuant to the Placement Agreement (before deducting
expenses) of the Registrable Securities to which such Losses relate. Benefits
received by any Holder shall be deemed to be equal to the value of receiving
Registrable Securities that are registered under the Securities Act. The
relative fault of the Holders on the one hand and the Company on the other hand
shall be determined by reference to, among other things, whether the untrue or
alleged untrue statement of a material fact or the omission or alleged omission
to state a material fact relates to information supplied by the Holders or by
the Company, and the parties' relative intent, knowledge, access to information
and opportunity to correct or prevent such statement or omission. The Holders'
respective obligations to contribute pursuant to this paragraph are several in
proportion to the respective number of Registrable Securities they have sold
pursuant to a Registration Statement, and not joint.

        The parties hereto agree that it would not be just and equitable if
contribution pursuant to this Section 6(d) were determined by pro rata
allocation or by any other method or allocation that does not take into account
the equitable considerations referred to in the immediately preceding paragraph.
The amount paid or payable by an indemnified party as a result of the Losses
referred to in the immediately preceding paragraph shall be deemed to include,
subject to the limitations set forth above, any legal or other expenses
reasonably incurred by such indemnified party in connection with investigating
or defending any such action or claim. Notwithstanding this Section 6(d), an
indemnifying party that is a selling Holder of Registrable Securities shall not
be required to contribute any amount in excess of the amount by which the total
price at which the Registrable Securities sold by such indemnifying party and
distributed to the public were offered to the public exceeds the amount of any
damages that such indemnifying party has otherwise been required to pay by
reason of such untrue or alleged untrue statement or omission or alleged
omission. No person guilty of fraudulent misrepresentation (within the meaning
of Section 11(f) of the Securities Act) shall be entitled to contribution from
any person who was not guilty of such fraudulent misrepresentation.

            (e) The indemnity, contribution and expense reimbursement
obligations of the parties hereunder shall be in addition to any liability any
indemnified party may otherwise have hereunder, under the Placement Agreement or
otherwise.

            (f) The indemnity and contribution provisions contained in this
Section 6 shall remain operative and in full force and effect regardless of (i)
any termination of this Agreement, (ii) any investigation made by or on behalf
of any Holder or any person controlling

                                       16
<PAGE>   17

any Holder, or the Company, or the Company's officers or directors or any person
controlling the Company and (iii) the sale of any Registrable Securities by any
Holder.

        SECTION 7. INFORMATION REQUIREMENTS.

            (a) The Company covenants that, if at any time before the end of the
Effectiveness Period the Company is not subject to the reporting requirements of
the Exchange Act, it will cooperate with any Holder of Registrable Securities
and take such further reasonable action as any Holder of Registrable Securities
may reasonably request in writing (including, without limitation, making such
reasonable representations as any such Holder may reasonably request), all to
the extent required from time to time to enable such Holder to sell Registrable
Securities without registration under the Securities Act within the limitation
of the exemptions provided by Rule 144 and Rule 144A under the Securities Act
and customarily taken in connection with sales pursuant to such exemptions. Upon
the written request of any Holder of Registrable Securities, the Company shall
deliver to such Holder a written statement as to whether it has complied with
such filing requirements, unless such a statement has been included in the
Company's most recent report filed pursuant to Section 13 or Section 15(d) of
Exchange Act. Notwithstanding the foregoing, nothing in this Section 7 shall be
deemed to require the Company to register any of its securities (other than the
Common Stock) under any section of the Exchange Act.

        SECTION 8. MISCELLANEOUS.

            (a) No Conflicting Agreements. The Company is not, as of the date
hereof, a party to, nor shall it, on or after the date of this Agreement, enter
into, any agreement with respect to its securities that conflicts with the
rights granted to the Holders of Registrable Securities in this Agreement. The
Company represents and warrants that the rights granted to the Holders of
Registrable Securities hereunder do not in any way conflict with the rights
granted to the holders of the Company's securities under any other agreements.

            (b) Amendments and Waivers. The provisions of this Agreement,
including the provisions of this sentence, may not be amended, modified or
supplemented, and waivers or consents to departures from the provisions hereof
may not be given, unless the Company has obtained the written consent of Holders
of a majority of the then outstanding Underlying Common Stock constituting
Registrable Securities (with Holders of Debentures deemed to be the Holders, for
purposes of this Section, of the number of outstanding shares of Underlying
Common Stock into which such Debentures are or would be convertible or
exchangeable as of the date on which such consent is requested). Notwithstanding
the foregoing, a waiver or consent to depart from the provisions hereof with
respect to a matter that relates exclusively to the rights of Holders of
Registrable Securities whose securities are being sold pursuant to a
Registration Statement and that does not directly or indirectly affect the
rights of other Holders of Registrable Securities may be given by Holders of at
least a majority of the Registrable Securities being sold by such Holders
pursuant to such Registration Statement; provided, that the provisions of this
sentence may not be amended, modified, or supplemented except in accordance with
the provisions of the immediately preceding sentence. Each Holder of Registrable
Securities outstanding at the time of any such amendment, modification,
supplement, waiver or consent or thereafter shall be bound by any such
amendment, modification,

                                       17
<PAGE>   18

supplement, waiver or consent effected pursuant to this Section 8(b), whether or
not any notice, writing or marking indicating such amendment, modification,
supplement, waiver or consent appears on the Registrable Securities or is
delivered to such Holder.

            (c) Notices. All notices and other communications provided for or
permitted hereunder shall be made in writing by hand delivery, by telecopier, by
courier guaranteeing overnight delivery or by first-class mail, return receipt
requested, and shall be deemed given (i) when made, if made by hand delivery,
(ii) upon confirmation, if made by telecopier, (iii) one (1) Business Day after
being deposited with such courier, if made by overnight courier or (iv) on the
date indicated on the notice of receipt, if made by first-class mail, to the
parties as follows:

               (w)    if to a Holder of Registrable Securities, at the most
                      current address given by such Holder to the Company in a
                      Notice and Questionnaire or any amendment thereto;

               (x)    if to the Company, to:

                      Sanmina Corporation
                      2700 North First Street
                      San Jose, CA 95134
                      Attention:     Chief Financial Officer
                      Telecopy No.:  (408) 954-1401

                      and

                      Wilson Sonsini Goodrich & Rosati
                      650 Page Mill Road
                      Palo Alto, California 94304-1050
                      Attention: Chris Mitchell, Esq.
                      Telecopy No.: (650) 493-6811

                      (y) if to the Placement Agents, to:

                      Morgan Stanley & Co. Incorporated
                      1585 Broadway
                      New York, New York  10036
                      Attention:     Equity Capital Markets
                      Telecopy No.:  (212) 761-0356

                      and

                      Simpson Thacher & Bartlett
                      3373 Hillview Avenue, Suite 250
                      Palo Alto, California 94304
                      Attention: William H. Hinman, Esq.
                      Telecopy No.: (650) 251-5002

                                       18
<PAGE>   19

or to such other address as such person may have furnished to the other persons
identified in this Section 8(c) in writing in accordance herewith.

            (d) Approval of Holders. Whenever the consent or approval of Holders
of a specified percentage of Registrable Securities is required hereunder,
Registrable Securities held by the Company or its affiliates (as such term is
defined in Rule 405 under the Securities Act) (other than the Placement Agents
or subsequent Holders of Registrable Securities if such subsequent Holders are
deemed to be such affiliates solely by reason of their holdings f such
Registrable Securities) shall not be counted in determining whether such consent
or approval was given by the Holders of such required percentage.

            (e) Successors and Assigns. Any person who purchases any Registrable
Securities from the Placement Agents shall be deemed, for purposes of this
Agreement, to be an assignee of the Placement Agents. This Agreement shall inure
to the benefit of and be binding upon the successors and assigns of each of the
parties and shall inure to the benefit of and be binding upon each Holder of any
Registrable Securities.

            (f) Counterparts. This Agreement may be executed in any number of
counterparts and by the parties hereto in separate counterparts, each of which
when so executed shall be deemed to be original and all of which taken together
shall constitute one and the same agreement.

            (g) Headings. The headings in this Agreement are for convenience of
reference only and shall not limit or otherwise affect the meaning hereof.

            (h) Governing Law. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED
IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.

            (i) Severability. If any term provision, covenant or restriction of
this Agreement is held to be invalid, illegal, void or unenforceable, the
remainder of the terms, provisions, covenants and restrictions set forth herein
shall remain in full force and effect and shall in no way be affected, impaired
or invalidated thereby, and the parties hereto shall use their best efforts to
find and employ an alternative means to achieve the same or substantially the
same result as that contemplated by such term, provision, covenant or
restriction, it being intended that all of the rights and privileges of the
parties shall be enforceable to the fullest extent permitted by law.

            (j) Entire Agreement. This Agreement is intended by the parties as a
final expression of their agreement and is intended to be a complete and
exclusive statement of the agreement and understanding of the parties hereto in
respect of the subject matter contained herein and the registration rights
granted by the Company with respect to the Registrable Securities. Except as
provided in the Placement Agreement, there are no restrictions, promises,
warranties or undertakings, other than those set forth or referred to herein,
with respect to the registration rights granted by the Company with respect to
the Registrable Securities. This Agreement supersedes all prior agreements and
undertakings among the parties with respect to such registration rights. No
party hereto shall have any rights, duties or obligations other than

                                       19
<PAGE>   20

those specifically set forth in this Agreement. In no event will such methods of
distribution take the form of an underwritten offering of the Registrable
Securities without the prior agreement of the Company.

            (k) Termination. This Agreement and the obligations of the parties
hereunder shall terminate upon the end of the Effectiveness Period, except for
any liabilities or obligations under Section 4, 5 or 6 hereof and the
obligations to make payments of and provide for Additional Interest under
Section 2(e) hereof to the extent such damages accrue prior to the end of the
Effectiveness Period, each of which shall remain in effect in accordance with
its terms.

                                       20
<PAGE>   21

        IN WITNESS WHEREOF, the parties have executed this Agreement is of the
date first written above.

                                              SANMINA CORPORATION

                                              By: /s/ JURE SOLA
                                                  -------------------------
                                                  Name: Jure Sola
                                                  Title: Chief Executive Officer

Confirmed and accepted as of the date first above written:

MORGAN STANLEY & CO. INCORPORATED
BANC OF AMERICA SECURITIES LLC

By:  Morgan Stanley & Co. Incorporated

By: /s/ WILLIAM R. SALISBURY
   -------------------------------------
      Name: William R. Salisbury
      Title: Managing Director<PAGE>   1

                                                                     EXHIBIT 4.2

                                 DIADEXUS, INC.

                           INVESTORS' RIGHTS AGREEMENT

                                  April 6, 2000

<PAGE>   2

                                TABLE OF CONTENTS

<TABLE>
<S>   <C>                                                                    <C>
1.    REGISTRATION RIGHTS                                                      1

1.1   Definitions                                                              1
1.2   Request for Registration                                                 2
1.3   Company Registration                                                     4
1.4   Form S-3 Registration                                                    4
1.5   Obligations of the Company                                               5
1.6   Furnish Information                                                      6
1.7   Expenses of Registration                                                 7
1.8   Underwriting Requirements                                                7
1.9   Delay of Registration                                                    8
1.10  Indemnification                                                          8
1.11  Reports Under Securities Exchange Act of 1934                           10
1.12  Assignment of Registration Rights                                       11
1.13  Limitations on Subsequent Registration Rights                           11
1.14  Market-Standoff Agreement                                               11
1.15  Termination of Registration Rights                                      12

2.    COVENANTS OF THE COMPANY                                                12

2.1   Delivery of Financial Statements                                        12
2.2   Inspection                                                              13
2.3   Reservation of Common Stock                                             13
2.4   Proprietary Information and Inventions Agreement                        13
2.5   Right of First Offer                                                    13
2.6   Company Right of First Offer                                            15
2.7   Termination of Covenants                                                15

3.    MISCELLANEOUS                                                           16

3.1   Successors and Assigns                                                  16
3.2   Amendments and Waivers                                                  16
3.3   Notices                                                                 16
3.4   Severability                                                            16
3.5   Governing Law                                                           17
3.6   Counterparts                                                            17
3.7   Titles and Subtitles                                                    17
3.8   Aggregation of Stock                                                    17
</TABLE>

<PAGE>   3

                                 DIADEXUS, INC.

                           INVESTORS' RIGHTS AGREEMENT

        This Investors' Rights Agreement (the "Agreement") is made as of the 6th
day of April, 2000, by and among diaDexus, Inc., a Delaware corporation (the
"Company"), the investors listed on Exhibit A hereto, each of which is herein
referred to as an "Investor," and SmithKline Beecham Corporation and Incyte
Pharmaceuticals, Inc., each of whom is herein referred to as a "Founder".

                                    RECITALS

        The Company and the Investors have entered into a Series C Preferred
Stock Purchase Agreement (the "Purchase Agreement") of even date herewith
pursuant to which the Company desires to sell to the Investors and the Investors
desire to purchase from the Company shares of the Company's Series C Preferred
Stock (the "Series C Stock"). A condition to the Investors' obligations under
the Purchase Agreement is that the Company, the Founders and the Investors enter
into this Agreement in order to provide the Founders and Investors with certain
rights to register shares of the Company's Common Stock, par value $0.01 per
share (the "Common Stock"), issuable upon conversion of the Series C Stock held
by them. In addition, certain Major Investors will be granted certain rights to
receive or inspect information pertaining to the Company, and a right of first
offer with respect to certain issuances by the Company of its securities. The
Company, the Investors and the Founders each desire to induce the Investors to
purchase shares of Series C Stock pursuant to the Purchase Agreement by agreeing
to the terms and conditions set forth herein. The Founders are holders of the
Company's Series A Preferred Stock (the "Series A Stock") or the Series B
Preferred Stock (the "Series B Stock," and together with the Series A Stock and
the Series C Stock the "Preferred Stock").

                                    AGREEMENT

        The parties hereby agree as follows:

1. Registration Rights. The Company and the Investors covenant and agree as
follows:

        1.1 DEFINITIONS. For purposes of this Section 1:

                (a) The terms "register," "registered," and "registration" refer
to a registration effected by preparing and filing a registration statement or
similar document in compliance with the Securities Act of 1933, as amended (the
"Securities Act"), and the declaration or ordering of effectiveness of such
registration statement or document;

                (b) The term "Registrable Securities" means (i) the shares of
Common Stock issuable or issued upon conversion of the Preferred Stock, and (ii)
any other shares of Common

<PAGE>   4

Stock of the Company issued as (or issuable upon the conversion or exercise of
any warrant, right or other security which is issued as) a dividend or other
distribution with respect to, or in exchange for or in replacement of, the
shares listed in (i); provided, however, that the foregoing definition shall
exclude in all cases any Registrable Securities sold by a person in a
transaction in which his or her rights under this Agreement are not assigned.
Notwithstanding the foregoing, Common Stock or other securities shall only be
treated as Registrable Securities if and so long as they have not been (A) sold
to or through a broker or dealer or underwriter in a public distribution or a
public securities transaction, or (B) sold in a transaction exempt from the
registration and prospectus delivery requirements of the Securities Act under
Section 4(1) thereof so that all transfer restrictions, and restrictive legends
with respect thereto, if any, are removed upon the consummation of such sale;

                (c) The number of shares of "Registrable Securities then
outstanding" shall be determined by the number of shares of Common Stock
outstanding which are, and the number of shares of Common Stock issuable
pursuant to then exercisable or convertible securities which are, Registrable
Securities;

                (d) The term "Holder" means any person owning or having the
right to acquire Registrable Securities or any assignee thereof in accordance
with Section 1.12 of this Agreement;

                (e) The term "Form S-3" means such form under the Securities Act
as in effect on the date hereof or any successor form under the Securities Act;

                (f) The term "SEC" means the Securities and Exchange Commission;
and

                (g) The term "Qualified IPO" means a firm commitment
underwritten public offering by the Company of shares of its Common Stock
pursuant to a registration statement on Form S-1 under the Securities Act, the
public offering price of which is not less than $12.00 per share (appropriately
adjusted for any stock split, dividend, combination or other recapitalization)
and which results in aggregate cash proceeds to the Company of at least
$20,000,000 (prior to underwriting discounts and commissions).

        1.2 REQUEST FOR REGISTRATION.

                (a) If the Company shall receive at any time after the 180th day
following the effective date of the first registration statement for a public
offering of securities of the Company (other than a registration statement
relating either to the sale of securities to employees of the Company pursuant
to a stock option, stock purchase or similar plan or an SEC Rule 145
transaction), a written request from the Holders of at least forty percent (40%)
of the Registrable Securities then outstanding that the Company file a
registration statement under the Securities Act, then the Company shall, within
ten (10) days of the receipt thereof, give written notice of such request to all
Holders and shall, subject to the limitations of subsection 1.2(b), use its best
efforts to effect as soon as practicable, and in any event within 60 days of the
receipt of such request, the registration under the Securities Act of all
Registrable Securities which the Holders request to be registered within twenty
(20) days of the mailing of such notice by the Company in accordance with
Section 3.3.

                                      -2-
<PAGE>   5

                (b) If the Holders initiating the registration request hereunder
("Initiating Holders") intend to distribute the Registrable Securities covered
by their request by means of an underwriting, they shall so advise the Company
as a part of their request made pursuant to this Section 1.2 and the Company
shall include such information in the written notice referred to in subsection
1.2(a). The underwriter will be selected by a majority in interest of the
Initiating Holders and shall be reasonably acceptable to the Company. In such
event, the right of any Holder to include his Registrable Securities in such
registration shall be conditioned upon such Holder's participation in such
underwriting and the inclusion of such Holder's Registrable Securities in the
underwriting (unless otherwise mutually agreed by a majority in interest of the
Initiating Holders and such Holder) to the extent provided herein. All Holders
proposing to distribute their securities through such underwriting shall
(together with the Company as provided in subsection 1.5(e)) enter into an
underwriting agreement in customary form with the underwriter or underwriters
selected for such underwriting. Notwithstanding any other provision of this
Section 1.2, if the underwriter advises the Initiating Holders in writing that
marketing factors require a limitation of the number of shares to be
underwritten, then the Initiating Holders shall so advise all Holders of
Registrable Securities which would otherwise be underwritten pursuant hereto,
and the number of shares of Registrable Securities that may be included in the
underwriting shall be allocated among all Holders thereof, including the
Initiating Holders, in proportion (as nearly as practicable) to the amount of
Registrable Securities of the Company owned by each Holder; provided, however,
that the number of shares of Registrable Securities to be included in such
underwriting shall not be reduced unless all other securities are first entirely
excluded from the underwriting.

                (c) Notwithstanding the foregoing, if the Company shall furnish
to Holders requesting a registration statement pursuant to this Section 1.2, a
certificate signed by the President of the Company stating that in the good
faith judgment of the Board of Directors of the Company, it would be seriously
detrimental to the Company and its shareholders for such registration statement
to be filed and it is therefore essential to defer the filing of such
registration statement, the Company shall have the right to defer such filing
for a period of not more than 120 days after receipt of the request of the
Initiating Holders; provided, however, that the Company may not utilize this
right more than once in any twelve-month period.

                (d) In addition, the Company shall not be obligated to effect,
or to take any action to effect, any registration pursuant to this Section 1.2:

                        (i) After the Company has effected two (2) registrations
pursuant to this Section 1.2 and such registrations have been declared or
ordered effective;

                        (ii) If the aggregate offering price to the public, as
shown on the cover of the registration statement, of the Registrable Securities
to be registered would be less than $7,500,000;

                        (iii) During the period starting with the date sixty
(60) days prior to the Company's good faith estimate of the date of filing of,
and ending on a date one hundred eighty (180) days after the effective date of,
a registration subject to Section 1.3 hereof; provided that the Company is
actively employing in good faith all reasonable efforts to cause such
registration

                                      -3-
<PAGE>   6

statement to become effective; and provided further that the Company notifies
the Initiating Holders within 20 days of their request for registration of its
intention to file such a registration within 60 days of the Company's notice; or

                        (iv) If the Initiating Holders propose to dispose of
shares of Registrable Securities that may be immediately registered on Form S-3
pursuant to a request made pursuant to Section 1.4 below.

        1.3 COMPANY REGISTRATION. If (but without any obligation to do so) the
Company proposes to register (including for this purpose a registration effected
by the Company for shareholders other than the Holders) any of its stock under
the Securities Act in connection with the public offering of such securities
solely for cash (other than a registration relating solely to the sale of
securities to participants in a Company stock plan or a transaction covered by
Rule 145 under the Securities Act), the Company shall, at such time, promptly
give each Holder written notice of such registration. Upon the written request
of each Holder given within twenty (20) days after mailing of such notice by the
Company in accordance with Section 3.3, the Company shall, subject to the
provisions of Section 1.8, cause to be registered under the Securities Act all
of the Registrable Securities that each such Holder has requested to be
registered.

        1.4 FORM S-3 REGISTRATION. In case the Company shall receive from any
Holder or Holders of Registrable Securities representing not less than 500,000
shares of Common Stock (as adjusted for stock splits, stock dividends and stock
combinations) a written request or requests that the Company effect a
registration on Form S-3 and any related qualification or compliance with
respect to all or a part of the Registrable Securities owned by such Holder or
Holders, the Company will:

                (a) promptly give written notice of the proposed registration,
and any related qualification or compliance, to all other Holders; and

                        (i) as soon as practicable, effect such registration and
all such qualifications and compliances as may be so requested and as would
permit or facilitate the sale and distribution of all or such portion of such
Holder's or Holders' Registrable Securities as are specified in such request,
together with all or such portion of the Registrable Securities of any other
Holder or Holders joining in such request as are specified in a written request
given within 15 days after receipt of such written notice from the Company;
provided, however, that the Company shall not be obligated to effect any such
registration, qualification or compliance, pursuant to this Section 1.4: (i) if
Form S-3 is not available for such offering by the Holders; (ii) if the Holders,
together with the holders of any other securities of the Company entitled to
inclusion in such registration, propose to sell Registrable Securities and such
other securities (if any) at an aggregate price to the public (net of any
underwriters' discounts or commissions) of less than $1,000,000; (iii) if the
Company shall furnish to the Holders a certificate signed by the President of
the Company stating that in the good faith judgment of the Board of Directors of
the Company, it would be seriously detrimental to the Company and its
shareholders for such Form S-3 Registration to be effected at such time, in
which event the Company shall have the right to defer the filing of the Form S-3
registration statement for a period of not more than 120

                                      -4-
<PAGE>   7

days after receipt of the request of the Holder or Holders under this Section
1.4; provided, however, that the Company shall not utilize this right more than
once in any twelve month period; (iv) after the Company has effected two (2)
registrations pursuant to this Section 1.4 and such registrations have been
declared or ordered effective; (v) if the Company has, within the six (6) month
period preceding the date of such request, already effected a registration on
Form S-3 for the Holders pursuant to this Section 1.4; (vi) in any particular
jurisdiction in which the Company would be required to qualify to do business or
to execute a general consent to service of process in effecting such
registration, qualification or compliance; or (vii) during the period ending one
hundred eighty (180) days after the effective date of a registration statement
subject to Section 1.3.

                (b) Subject to the foregoing, the Company shall file a
registration statement covering the Registrable Securities and other securities
so requested to be registered as soon as practicable after receipt of the
request or requests of the Holders. Registrations effected pursuant to this
Section 1.4 shall not be counted as demands for registration or registrations
effected pursuant to Sections 1.2 or 1.3, respectively.

        1.5 OBLIGATIONS OF THE COMPANY. Whenever required under this Section 1
to effect the registration of any Registrable Securities, the Company shall, as
expeditiously as reasonably possible:

                (a) Prepare and file with the SEC a registration statement with
respect to such Registrable Securities and use its best efforts to cause such
registration statement to become effective, and, upon the request of the Holders
of a majority of the Registrable Securities registered thereunder, keep such
registration statement effective for up to one hundred twenty (120) days. The
Company shall not be required to file, cause to become effective or maintain the
effectiveness of any registration statement that contemplates a distribution of
securities on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act.

                (b) Prepare and file with the SEC such amendments and
supplements to such registration statement and the prospectus used in connection
with such registration statement as may be necessary to comply with the
provisions of the Securities Act with respect to the disposition of all
securities covered by such registration statement for up to one hundred twenty
(120) days.

                (c) Furnish to the Holders such numbers of copies of a
prospectus, including a preliminary prospectus, in conformity with the
requirements of the Securities Act, and such other documents as they may
reasonably request in order to facilitate the disposition of Registrable
Securities owned by them.

                (d) Use its best efforts to register and qualify the securities
covered by such registration statement under such other securities or blue sky
laws of such jurisdictions as shall be reasonably requested by the Holders,
provided that the Company shall not be required in connection therewith or as a
condition thereto to qualify to do business or to file a general consent to
service of process in any such states or jurisdictions.

                                      -5-
<PAGE>   8

                (e) In the event of any underwritten public offering, enter into
and perform its obligations under an underwriting agreement, in usual and
customary form, with the managing underwriter of such offering. Each Holder
participating in such underwriting shall also enter into and perform its
obligations under such an agreement.

                (f) Notify each Holder of Registrable Securities covered by such
registration statement at any time when a prospectus relating thereto is
required to be delivered under the Securities Act of the happening of any event
as a result of which the prospectus included in such registration statement, as
then in effect, includes an untrue statement of a material fact or omits to
state a material fact required to be stated therein or necessary to make the
statements therein not misleading in the light of the circumstances then
existing, such obligation to continue for one hundred twenty (120) days. The
Company will use reasonable efforts to amend or supplement such prospectus in
order to cause such prospectus not to include any untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary
to make the statements therein not misleading in the light of the circumstances
then existing.

                (g) Cause all such Registrable Securities registered pursuant
hereunder to be listed on each securities exchange on which similar securities
issued by the Company are then listed.

                (h) Provide a transfer agent and registrar for all Registrable
Securities registered pursuant hereunder and a CUSIP number for all such
Registrable Securities, in each case not later than the effective date of such
registration.

                (i) Use its best efforts to furnish, at the request of any
Holder requesting registration of Registrable Securities pursuant to this
Section 1, on the date that such Registrable Securities are delivered to the
underwriters for sale in connection with a registration pursuant to this Section
1, if such securities are being sold through underwriters, (i) an opinion, dated
such date, of the counsel representing the Company for the purposes of such
registration, in form and substance as is customarily given to underwriters in
an underwritten public offering, addressed to the underwriters, and (ii) a
letter dated such date, from the independent certified public accountants of the
Company, in form and substance as is customarily given by independent certified
public accountants to underwriters in an underwritten public offering, addressed
to the underwriters.

        1.6 FURNISH INFORMATION. It shall be a condition precedent to the
obligations of the Company to take any action pursuant to this Section 1 with
respect to the Registrable Securities of any selling Holder that such Holder
shall furnish to the Company such information regarding itself, the Registrable
Securities held by it, and the intended method of disposition of such securities
as shall be required to effect the registration of such Holder's Registrable
Securities. The Company shall have no obligation with respect to any
registration requested pursuant to Section 1.2 or Section 1.4 of this Agreement
if, as a result of the application of the preceding sentence, the number of
shares or the anticipated aggregate offering price of the Registrable Securities
to be included in the registration does not equal or exceed the number of shares
or the anticipated aggregate offering price required to originally trigger the
Company's obligation to

                                      -6-
<PAGE>   9

initiate such registration as specified in subsection 1.2(d) or subsection
1.4(b), whichever is applicable.

        1.7 EXPENSES OF REGISTRATION.

                (a) DEMAND REGISTRATION AND REGISTRATION ON FORM S-3. All
expenses other than underwriting discounts and commissions incurred in
connection with registrations, filings or qualifications pursuant to Sections
1.2 and 1.4, including (without limitation) all registration, filing and
qualification fees, printers' and accounting fees, fees and disbursements of
counsel for the Company, and the reasonable fees and disbursements of one
counsel for the selling Holders selected by them with the approval of the
Company, which approval shall not be unreasonably withheld, shall be borne by
the Company; provided, however, that the Company shall not be required to pay
for any expenses of any registration proceeding begun pursuant to Section 1.2 or
Section 1.4 if the registration request is subsequently withdrawn at the request
of the Holders who requested registration (in which case all participating
Holders shall bear such expenses), unless (i) in the case of a registration
pursuant to Section 1.2, the Holders of at least forty percent (40%) of the
Registrable Securities then outstanding agree to forfeit their right to one
demand registration pursuant to Section 1.2, or (ii) the withdrawal is based
upon material adverse information concerning the Company of which the Holders
were not aware at the time of such request.

                (b) COMPANY REGISTRATION. All expenses other than underwriting
discounts and commissions incurred in connection with registrations, filings or
qualifications of Registrable Securities pursuant to Section 1.3 for each Holder
(which right may be assigned as provided in Section 1.12), including (without
limitation) all registration, filing, and qualification fees, printers' and
accounting fees, fees and disbursements of counsel for the Company and the
reasonable fees and disbursements of one counsel for the selling Holder or
Holders selected by them with the approval of the Company, which approval shall
not be unreasonably withheld, shall be borne by the Company.

        1.8 UNDERWRITING REQUIREMENTS. In connection with any offering involving
an underwriting of shares of the Company's capital stock, the Company shall not
be required under Section 1.3 to include any of the Holders' securities in such
underwriting unless they accept the terms of the underwriting as agreed upon
between the Company and the underwriters selected by it (or by other persons
entitled to select the underwriters), and then only in such quantity as the
underwriters determine in their sole discretion will not jeopardize the success
of the offering by the Company. If the total amount of securities, including
Registrable Securities, requested by shareholders to be included in such
offering exceeds the amount of securities sold other than by the Company that
the underwriters determine in their sole discretion is compatible with the
success of the offering, then the Company shall be required to include in the
offering only that number of such securities, including Registrable Securities,
which the underwriters determine in their sole discretion will not jeopardize
the success of the offering (the securities so included to be apportioned pro
rata among the selling shareholders according to the total amount of securities
entitled to be included therein owned by each selling shareholder or in such
other proportions as shall mutually be agreed to by such selling shareholders)
but in no event shall the amount of securities of the selling Holders included
in the offering be reduced below thirty percent (30%) of

                                      -7-
<PAGE>   10

the total amount of securities included in such offering, unless such offering
is the initial public offering of the Company's securities, in which case, the
selling shareholders may be excluded if the underwriters make the determination
described above and no other shareholder's securities are included. For purposes
of the preceding parenthetical concerning apportionment, for any selling
shareholder which is a holder of Registrable Securities and which is a
partnership or corporation, the partners, retired partners and shareholders of
such holder, or the estates and family members of any such partners and retired
partners and any trusts for the benefit of any of the foregoing persons shall be
deemed to be a single "selling shareholder," and any pro-rata reduction with
respect to such "selling shareholder" shall be based upon the aggregate amount
of shares carrying registration rights owned by all entities and individuals
included in such "selling shareholder," as defined in this sentence.

        1.9 DELAY OF REGISTRATION. No Holder shall have any right to obtain or
seek an injunction restraining or otherwise delaying any such registration as
the result of any controversy that might arise with respect to the
interpretation or implementation of this Section 1.

        1.10 INDEMNIFICATION. In the event any Registrable Securities are
included in a registration statement under this Section 1:

                (a) To the extent permitted by law, the Company will indemnify
and hold harmless each Holder, any underwriter (as defined in the Securities
Act) for such Holder and each person, if any, who controls such Holder or
underwriter within the meaning of the Securities Act or the Securities Exchange
Act of 1934, as amended (the "Exchange Act"), against any losses, claims,
damages, or liabilities (joint or several) to which they may become subject
under the Securities Act, the Exchange Act or other federal or state law,
insofar as such losses, claims, damages, or liabilities (or actions in respect
thereof) arise out of or are based upon any of the following statements,
omissions or violations (collectively a "Violation"): (i) any untrue statement
or alleged untrue statement of a material fact contained in such registration
statement, including any preliminary prospectus or final prospectus contained
therein or any amendments or supplements thereto, (ii) the omission or alleged
omission to state therein a material fact required to be stated therein, or
necessary to make the statements therein not misleading, or (iii) any violation
or alleged violation by the Company of the Securities Act, the Exchange Act, any
state securities law or any rule or regulation promulgated under the Securities
Act, the Exchange Act or any state securities law; and the Company will pay to
each such Holder, underwriter or controlling person, as incurred, any legal or
other expenses reasonably incurred by them in connection with investigating or
defending any such loss, claim, damage, liability, or action; provided, however,
that the indemnity agreement contained in this subsection 1.10(a) shall not
apply to amounts paid in settlement of any such loss, claim, damage, liability,
or action if such settlement is effected without the consent of the Company
(which consent shall not be unreasonably withheld), nor shall the Company be
liable to any Holder, underwriter or controlling person for any such loss,
claim, damage, liability, or action to the extent that it arises out of or is
based upon a Violation which occurs in reliance upon and in conformity with
written information furnished expressly for use in connection with such
registration by any such Holder, underwriter or controlling person.

                                      -8-
<PAGE>   11

                (b) To the extent permitted by law, each selling Holder will
indemnify and hold harmless the Company, each of its directors, each of its
officers who has signed the registration statement, each person, if any, who
controls the Company within the meaning of the Securities Act, any underwriter,
any other Holder selling securities in such registration statement and any
controlling person of any such underwriter or other Holder, against any losses,
claims, damages, or liabilities (joint or several) to which any of the foregoing
persons may become subject, under the Securities Act, the Exchange Act or other
federal or state law, insofar as such losses, claims, damages, or liabilities
(or actions in respect thereto) arise out of or are based upon any Violation, in
each case to the extent (and only to the extent) that such Violation occurs in
reliance upon and in conformity with written information furnished by such
Holder under an instrument duly executed by such Holder and stated to be
expressly for use in connection with such registration; and each such Holder
will pay, as incurred, any legal or other expenses reasonably incurred by any
person intended to be indemnified pursuant to this subsection 1.10(b), in
connection with investigating or defending any such loss, claim, damage,
liability, or action; provided, however, that the indemnity agreement contained
in this subsection 1.10(b) shall not apply to amounts paid in settlement of any
such loss, claim, damage, liability or action if such settlement is effected
without the consent of the Holder, which consent shall not be unreasonably
withheld; provided, that in no event shall any indemnity under this subsection
1.10(b) exceed the net proceeds from the offering received by such Holder.

                (c) Promptly after receipt by an indemnified party under this
Section 1.10 of notice of the commencement of any action (including any
governmental action), such indemnified party will, if a claim in respect thereof
is to be made against any indemnifying party under this Section 1.10, deliver to
the indemnifying party a written notice of the commencement thereof and the
indemnifying party shall have the right to participate in, and, to the extent
the indemnifying party so desires, jointly with any other indemnifying party
similarly noticed, to assume the defense thereof with counsel mutually
satisfactory to the parties; provided, however, that an indemnified party
(together with all other indemnified parties which may be represented without
conflict by one counsel) shall have the right to retain one separate counsel,
with the reasonable fees and expenses to be paid by the indemnifying party, if
representation of such indemnified party by the counsel retained by the
indemnifying party would be inappropriate due to actual or potential differing
interests between such indemnified party and any other party represented by such
counsel in such proceeding. The failure to deliver written notice to the
indemnifying party within a reasonable time of the commencement of any such
action, if materially prejudicial to its ability to defend such action, shall
relieve such indemnifying party of any liability to the indemnified party under
this Section 1.10, but the omission so to deliver written notice to the
indemnifying party will not relieve it of any liability that it may have to any
indemnified party otherwise than under this Section 1.10. No Indemnifying Party,
in the defense of any such claim or litigation, shall except with the consent of
each Indemnified Party, consent to entry of any judgment or enter into any
settlement which does not include as an unconditional term thereof the giving by
the claimant or plaintiff to such Indemnified Party of a release from all
liability in respect to such claim or litigation.

                (d) If the indemnification provided for in this Section 1.10 is
held by a court of competent jurisdiction to be unavailable to an indemnified
party with respect to any loss, liability, claim, damage or expense referred to
therein, then the indemnifying party, in lieu of

                                      -9-
<PAGE>   12

indemnifying such indemnified party hereunder, shall contribute to the amount
paid or payable by such indemnified party as a result of such loss, liability,
claim, damage, or expense in such proportion as is appropriate to reflect the
relative fault of the indemnifying party on the one hand and of the indemnified
party on the other in connection with the statements or omissions that resulted
in such loss, liability, claim, damage or expense as well as any other relevant
equitable considerations; provided, that in no event shall any contribution by a
Holder under this Subsection 1.10(d) exceed the net proceeds from the offering
received by such Holder. The relative fault of the indemnifying party and of the
indemnified party shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or the
omission to state a material fact relates to information supplied by the
indemnifying party or by the indemnified party and the parties' relative intent,
knowledge, access to information, and opportunity to correct or prevent such
statement or omission.

                (e) The obligations of the Company and Holders under this
Section 1.10 shall survive the completion of any offering of Registrable
Securities in a registration statement under this Section 1, and otherwise.

        1.11 REPORTS UNDER SECURITIES EXCHANGE ACT OF 1934. With a view to
making available to the Holders the benefits of Rule 144 promulgated under the
Securities Act and any other rule or regulation of the SEC that may at any time
permit a Holder to sell securities of the Company to the public without
registration or pursuant to a registration on Form S-3, the Company agrees to:

                (a) make and keep public information available, as those terms
are understood and defined in SEC Rule 144, at all times after ninety (90) days
after the effective date of the first registration statement filed by the
Company for the offering of its securities to the general public so long as the
Company remains subject to the periodic reporting requirements under Sections 13
or 15(d) of the Exchange Act;

                (b) take such action, including the voluntary registration of
its Common Stock under Section 12 of the Exchange Act, as is necessary to enable
the Holders to utilize Form S-3 for the sale of their Registrable Securities,
such action to be taken as soon as practicable after the end of the fiscal year
in which the first registration statement filed by the Company for the offering
of its Common Stock to the general public is declared effective;

                (c) file with the SEC in a timely manner all reports and other
documents required of the Company under the Securities Act and the Exchange Act;
and

                (d) furnish to any Holder, so long as the Holder owns any
Registrable Securities, forthwith upon request (i) a written statement by the
Company that it has complied with the reporting requirements of SEC Rule 144 (at
any time after ninety (90) days after the effective date of the first
registration statement filed by the Company), the Securities Act and the
Exchange Act (at any time after it has become subject to such reporting
requirements), or that it qualifies as a registrant whose securities may be
resold pursuant to Form S-3 (at any time after it so qualifies), (ii) a copy of
the most recent annual or quarterly report of the Company and such other reports
and documents so filed by the Company, and (iii) such other information as may
be

                                      -10-
<PAGE>   13

reasonably requested in availing any Holder of any rule or regulation of the SEC
which permits the selling of any such securities without registration or
pursuant to such form.

        1.12 ASSIGNMENT OF REGISTRATION RIGHTS. The rights to cause the Company
to register Registrable Securities pursuant to this Section 1 may be assigned
(but only with all related obligations) by a Holder to a transferee or assignee
of at least 10,000 shares of such securities, provided the Company is, within a
reasonable time after such transfer, furnished with written notice of the name
and address of such transferee or assignee and the securities with respect to
which such registration rights are being assigned; and provided, further, that
such assignment shall be effective only if immediately following such transfer
the further disposition of such securities by the transferee or assignee is
restricted under the Securities Act. For the purposes of determining the number
of shares of Registrable Securities held by a transferee or assignee, the
holdings of transferees and assignees of a partnership who are partners or
retired partners of such partnership (including spouses and ancestors, lineal
descendants and siblings of such partners or spouses who acquire Registrable
Securities by gift, will or intestate succession) shall be aggregated together
and with the partnership; provided that all assignees and transferees who would
not qualify individually for assignment of registration rights shall have a
single attorney-in-fact for the purpose of exercising any rights, receiving
notices or taking any action under Section 1.

        1.13 LIMITATIONS ON SUBSEQUENT REGISTRATION RIGHTS. From and after the
date of this Agreement, the Company shall not, without the prior written consent
of the Holders of a majority of the outstanding Registrable Securities, enter
into any agreement with any holder or prospective holder of any securities of
the Company which would allow such holder or prospective holder (a) to include
such securities in any registration filed under Section 1.2 hereof, unless under
the terms of such agreement, such holder or prospective holder may include such
securities in any such registration only to the extent that the inclusion of his
securities will not reduce the amount of the Registrable Securities of the
Holders which is included or (b) to make a demand registration which could
result in such registration statement being declared effective prior to the date
set forth in subsection 1.2(a) or within one hundred twenty (120) days of the
effective date of any registration effected pursuant to Section 1.2.

        1.14 MARKET-STANDOFF AGREEMENT.

                (a) MARKET-STANDOFF PERIOD; AGREEMENT. In connection with the
initial public offering of the Company's securities and upon request of the
Company or the underwriters managing such offering of the Company's securities,
each Holder agrees not to sell, make any short sale of, loan, grant any option
for the purchase of, or otherwise dispose of any securities of the Company
(other than those included in the registration) without the prior written
consent of the Company or such underwriters, as the case may be, for such period
of time (not to exceed 180 days) from the effective date of such registration as
may be requested by the Company or such managing underwriters and to execute an
agreement reflecting the foregoing as may be requested by the underwriters at
the time of the Company's initial public offering. In addition, the Holder
agrees to be bound by similar restrictions, and to sign a similar agreement, in
connection with any one (but only one) additional registration statement filed
within 12 months after the closing date of the initial public offering, provided
that the duration of the market-standoff period with

                                      -11-
<PAGE>   14

respect to such additional registration shall not exceed 90 days from the
effective date of such additional registration.

                (b) LIMITATIONS. The obligations described in Section 1.14(a)
shall apply only if all officers and directors of the Company and all persons
holding 1% or more of the Common Stock (on a fully-diluted basis) enter into
similar agreements, and shall not apply to a registration relating solely to
employee benefit plans, or to a registration relating solely to a transaction
pursuant to Rule 145 under the Securities Act.

                (c) STOP-TRANSFER INSTRUCTIONS. In order to enforce the
foregoing covenants, the Company may impose stop-transfer instructions with
respect to the securities of each Holder (and the securities of every other
person subject to the restrictions in Section 1.14(a)).

                (d) TRANSFEREES BOUND. Each Holder agrees that it will not
transfer securities of the Company unless each transferee agrees in writing to
be bound by all of the provisions of this Section 1.14, provided that this
Section 1.14(d) shall not apply to transfers pursuant to a registration
statement.

        1.15 TERMINATION OF REGISTRATION RIGHTS. No Holder shall be entitled to
exercise any right provided for in this Section 1 after the earlier of (i) five
(5) years following the consummation of a Qualified IPO, or (ii) with respect to
any Holder, such time following a Qualified IPO as the Holder owns less than 1%
of the Common Stock (on an as-converted, fully diluted basis) and Rule 144 or
another similar exemption under the Securities Act is available for the sale of
all of such Holder's shares during a three (3)-month period without
registration.

2. COVENANTS OF THE COMPANY.

        2.1 DELIVERY OF FINANCIAL STATEMENTS. The Company shall deliver to each
Major Investor (as hereinafter defined):

                (a) as soon as practicable, but in any event within ninety (90)
days after the end of each fiscal year of the Company, an income statement for
such fiscal year, a balance sheet of the Company and statement of shareholder's
equity as of the end of such year, and a statement of cash flows for such year,
such year-end financial reports to be in reasonable detail, prepared in
accordance with generally accepted accounting principles ("GAAP"), and audited
and certified by an independent public accounting firm of nationally recognized
standing selected by the Company;

                (b) as soon as practicable, but in any event within thirty (30)
days after the end of each of the first three (3) quarters of each fiscal year
of the Company, an unaudited profit or loss statement, a statement of cash flows
for such fiscal quarter and an unaudited balance sheet as of the end of such
fiscal quarter;

                (c) as soon as practicable, but in any event twenty (20) days
prior to the end of each fiscal year, a budget and business plan for the next
fiscal year; and

                                      -12-
<PAGE>   15

                (d) with respect to the financial statements called for in
subsection (b) of this Section 2.1, an instrument executed by the Chief
Financial Officer or President of the Company certifying that such financials
were prepared in accordance with GAAP consistently applied with prior practice
for earlier periods (with the exception of footnotes that may be required by
GAAP) and fairly present the financial condition of the Company and its results
of operation for the period specified, subject to year-end audit adjustment,
provided that the foregoing shall not restrict the right of the Company to
change its accounting principles consistent with GAAP, if the Board of Directors
determines that it is in the best interest of the Company to do so.

                        "Major Investor" shall mean any person who together with
any general partners or other affiliates of such person, holds securities
representing (on an as-converted basis) not less than 500,000 shares of Common
Stock (as adjusted for stock splits, stock dividends and stock combinations).

        2.2 INSPECTION. The Company shall permit each Major Investor, at the
Major Investor's expense, to visit and inspect the Company's properties, to
examine its books of account and records and to discuss the Company's affairs,
finances and accounts with its officers, all at such reasonable times as may be
requested by the Major Investor; provided, however, that the Company shall not
be obligated pursuant to this Section 2.2 to provide access to any information
which it reasonably considers to be a trade secret or similar confidential
information.

        2.3 RESERVATION OF COMMON STOCK. The Company will at all times reserve
and keep available, solely for issuance and delivery upon the conversion of the
Preferred Stock, all Common Stock issuable from time to time upon such
conversion.

        2.4 PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT. The Company shall
require all managerial and technical personnel to execute an agreement regarding
confidentiality and proprietary information substantially in the form or forms
delivered to the counsel for the Investors.

        2.5 RIGHT OF FIRST OFFER. Subject to the terms and conditions specified
in this Section 2.5, the Company hereby grants to each Major Investor a right of
first offer with respect to future sales by the Company of its Shares (as
hereinafter defined). A Major Investor who chooses to exercise the right of
first offer may designate as purchasers under such right itself or its partners
or affiliates in such proportions as it deems appropriate.

                Each time the Company proposes to offer any shares of, or
securities convertible into or exercisable for any shares of, or any security
carrying any warrant or right to subscribe to purchase, any class of its capital
stock, or any such warrant or right ("Shares"), the Company shall first make an
offering of such Shares to each Major Investor in accordance with the following
provisions:

                (a) The Company shall deliver a notice by certified mail
("Notice") to the Major Investors stating (i) its bona fide intention to offer
such Shares, (ii) the number of such Shares to be offered, and (iii) the price
and terms, if any, upon which it proposes to offer such Shares.

                                      -13-
<PAGE>   16

                (b) Within 15 calendar days after delivery of the Notice, the
Major Investor may elect to purchase or obtain, at the price and on the terms
specified in the Notice, up to that portion of such Shares which equals the
proportion that the number of shares of Common Stock issued and held, or
issuable upon conversion and exercise of all convertible or exercisable
securities then held, by such Major Investor bears to the total number of shares
of Common Stock then outstanding (assuming full conversion and exercise of all
convertible or exercisable securities). The Company shall promptly, in writing,
inform each Major Investor that purchases all the shares available to it (each,
a "Fully-Exercising Investor") of any other Major Investor's failure to do
likewise. During the ten (10)-day period commencing after receipt of such
information, each Fully-Exercising Investor shall be entitled to obtain that
portion of the Shares for which Major Investors were entitled to subscribe but
which were not subscribed for by the Major Investors that is equal to the
proportion that the number of shares of Common Stock issued and held, or
issuable upon conversion and exercise of all convertible or exercisable
securities then held, by such Fully-Exercising Investor bears to the total
number of shares of Common Stock issued and held, or issuable upon conversion
and exercise of all convertible or exercisable securities then held, by all
Fully-Exercising Investors.

                (c) The Company may, during the 45-day period following the
expiration of the period provided in subsection 2.5(b) hereof, offer the
remaining unsubscribed portion of the Shares to any person or persons at a price
not less than, and upon terms no more favorable to the offeree than those
specified in the Notice. If the Company does not enter into an agreement for the
sale of the Shares within such period, or if such agreement is not consummated
within 45 days of the execution thereof, the right provided hereunder shall be
deemed to be revived and such Shares shall not be offered unless first reoffered
to the Major Investors in accordance herewith.

                (d) The right of first offer in this paragraph 2.5 shall not be
applicable (i) to the issuance or sale of up to 2,200,000 shares (or such
greater number as is unanimously approved by the Board of Directors) of Common
Stock (or options therefor) to employees, consultants and directors, pursuant to
plans or agreements approved by the Board of Directors for the primary purpose
of soliciting or retaining their services, (ii) to or after consummation of a
Qualified IPO, (iii) to the issuance of securities pursuant to the conversion or
exercise of convertible or exercisable securities, (iv) to the issuance of
securities in connection with a bona fide business acquisition of or by the
Company, whether by merger, consolidation, sale of assets, sale or exchange of
stock or otherwise, (v) to the issuance of securities to financial institutions
or lessors in connection with commercial credit arrangements, equipment
financings, or similar transactions, (vi) to the issuance or sale of the Series
C Stock, or (vii) to the issuance of securities that, with unanimous approval of
the Board of Directors of the Company, are not offered to any existing
shareholder of the Company.

                (e) Notwithstanding the foregoing, the right of first offer in
this Section 2.5 shall terminate with respect to any Major Investor who fails to
purchase all of such Major Investor's pro rata amount of Shares allocated to
such Major Investor pursuant to this Section 2.5.

                                      -14-
<PAGE>   17

                2.6 COMPANY RIGHT OF FIRST OFFER. No holder of Preferred Stock
(or a Permitted Transferee, as defined below) may sell or dispose, for value, of
any interest (a "Proposed Sale"), in any shares of Preferred Stock (the
"Shares"), other than to a Permitted Transferee, unless such holder (the
"Selling Holder") delivers a notice (the "Notice") to the Company at least 10
business days prior to the Proposed Sale setting forth the material terms and
conditions of the Proposed Sale including, without limitation, the number of
Shares proposed to be sold or transferred, and the form and amount of
consideration to be paid.

                (a) At any time within 10 business days from the date such
Notice is received by the Company, the Company shall have the right to deliver
to the Selling Holder notice of its irrevocable commitment to purchase all (but
not less than all) of the Shares at the same price and upon the same terms as
the Selling Holder proposes to sell the Shares in the Notice. If the Company
delivers to the Selling Holder notice of such irrevocable commitment within such
10-business-day period, the Company and the Selling Holder agree to execute a
definitive agreement with respect to the Proposed Sale within 45 days from the
date of the Company's notice. If the Company does not deliver to the Selling
Holder notice of such irrevocable commitment within such 10-business-day period,
then the Selling Holder shall have 90 days from the end of such period within
which to sell the Shares upon terms not materially less favorable to the Selling
Holder than those terms set forth in the Notice. If such 90-day period shall
expire without such a sale having been consummated, or if the Selling Holder
proposes to sell the Shares upon terms materially less favorable to the Selling
Holder than those terms set forth in the Notice, the Selling Holder shall again
comply with the procedures set forth in this Section 2.6.

                (b) "Permitted Transferee" shall mean any affiliate (as such
term is defined in Rule 405 promulgated under the Securities Act), partner,
member, beneficiary (in the case of a trust), family member, trust for the
benefit of family members, or family limited partnership. This Section 2.6 shall
not apply to any transfer by gift, will, or intestacy, or to any assignment by
operation of law or merger.

                (c) Each certificate representing shares of Preferred Stock
shall bear the following legend:

                "THE SHARES EVIDENCED HEREBY ARE SUBJECT TO CERTAIN RESTRICTIONS
                ON TRANSFER AS SET FORTH IN AN INVESTORS' RIGHTS AGREEMENT BY
                AND AMONG THE COMPANY AND ITS STOCKHOLDERS (A COPY OF WHICH MAY
                BE OBTAINED FROM THE COMPANY), AND BY ACCEPTING ANY INTEREST IN
                SUCH SHARES THE PERSON ACCEPTING SUCH INTEREST SHALL BECOME
                BOUND BY ALL THE PROVISIONS OF SAID INVESTORS' RIGHTS
                AGREEMENT."

                2.7 TERMINATION OF COVENANTS.

                (a) The covenants set forth in Sections 2.1 through Section 2.6
shall terminate as to each Investor and be of no further force or effect (i)
immediately prior to the consummation of a Qualified IPO, or (ii) when the
Company shall sell, convey, or otherwise dispose of or encumber all or
substantially all of its property or business or merge into or consolidate with
any

                                      -15-
<PAGE>   18

other corporation (other than a wholly-owned subsidiary corporation) or effect
any other transaction or series of related transactions in which more than fifty
percent (50%) of the voting power of the Company is disposed of, provided that
this subsection (ii) shall not apply to a merger effected exclusively for the
purpose of changing the domicile of the Corporation.

                (b) The covenants set forth in Sections 2.1 and 2.2 shall
terminate as to each Holder and be of no further force or effect when the
Company first becomes subject to the periodic reporting requirements of Sections
13 or 15(d) of the Exchange Act, if this occurs earlier than the events
described in Section 2.7(a) above.

3. MISCELLANEOUS.

        3.1 SUCCESSORS AND ASSIGNS. Except as otherwise provided in this
Agreement, the terms and conditions of this Agreement shall inure to the benefit
of and be binding upon the respective permitted successors and assigns of the
parties (including transferees of any of the Series C Preferred Stock or any
Common Stock issued upon conversion thereof). Nothing in this Agreement, express
or implied, is intended to confer upon any party other than the parties hereto
or their respective successors and assigns any rights, remedies, obligations, or
liabilities under or by reason of this Agreement, except as expressly provided
in this Agreement.

        3.2 AMENDMENTS AND WAIVERS. Any term of this Agreement may be amended or
waived only with the written consent of the Company and the holders of 80% of
the Registrable Securities then outstanding; provided that if such amendment has
the effect of affecting the Founders (i) in a manner different than securities
issued to the Investors and (ii) in a manner adverse to the interests of either
of the Founders, then such amendment shall require the consent of the affected
Founder. Any amendment or waiver effected in accordance with this paragraph
shall be binding upon each holder of any Registrable Securities then
outstanding, each future holder of all such Registrable Securities, and the
Company.

        3.3 NOTICES. Unless otherwise provided, any notice required or permitted
by this Agreement shall be in writing and shall be deemed sufficient upon
delivery, when delivered personally or by overnight courier or sent by telegram
or fax, or five days after being deposited in the U.S. mail, as certified or
registered mail, with postage prepaid, return receipt requested, and addressed
to the party to be notified at such party's address or fax number as set forth
below or on Exhibit A hereto or as subsequently modified by written notice.

        3.4 SEVERABILITY. If one or more provisions of this Agreement are held
to be unenforceable under applicable law, the parties agree to renegotiate such
provision in good faith. In the event that the parties cannot reach a mutually
agreeable and enforceable replacement for such provision, then (a) such
provision shall be excluded from this Agreement, (b) the balance of the
Agreement shall be interpreted as if such provision were so excluded and (c) the
balance of the Agreement shall be enforceable in accordance with its terms.

        3.5 GOVERNING LAW. This Agreement and all acts and transactions pursuant
hereto shall be governed, construed and interpreted in accordance with the laws
of the State of California, without giving effect to principles of conflicts of
laws.

                                      -16-
<PAGE>   19

        3.6 COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

        3.7 TITLES AND SUBTITLES. The titles and subtitles used in this
Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement.

        3.8 AGGREGATION OF STOCK. All shares of the Preferred Stock held or
acquired by affiliated entities or persons shall be aggregated together for the
purpose of determining the availability of any rights under this Agreement.

                            [Signature Page Follows]

                                      -17-
<PAGE>   20

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.

                                       -----------------------------------------
                                       (Investor)

By: /s/ Patrick Plewman                By:
    ------------------------------         -------------------------------------

                                       Name:
                                             -----------------------------------
Address:                                                  (print)
3303 Octavius Drive
Santa Clara, CA 95054

                                       Title:
                                              ----------------------------------

Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   21

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.
                                       -----------------------------------------
                                       (Investor)

By:                                    By:
    ------------------------------         -------------------------------------

                                       Name:
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054

                                       Title:
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

   /s/ Donald F. Parman
----------------------------------
SmithKline Beecham Corporation

By:       Donald F. Parman
Title:    Secretary

Address:  One Franklin Plaza
          Philadelphia, PA  19102

Fax:      215-751-3935

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   22

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.
                                       -----------------------------------------
                                       (Investor)

By:                                    By:
    ------------------------------         -------------------------------------

                                       Name:
                                             -----------------------------------
Address:                                                  (print)
3303 Octavius Drive
Santa Clara, CA 95054

                                       Title:
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

 /s/ Randal W. Scott
----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   23

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

                                       IDS Life Series Fund, Inc. -- Equity
                                       Portfolio
DIADEXUS, INC.                         (Investor)

By:                                    By: /s/ Frederick C. Quirsfeld
    ------------------------------         -------------------------------------

                                       Name:   Frederick C. Quirsfeld
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:  Vice President
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   24

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

                                       AXP Strategy Series, Inc.-- AXP
                                       Strategy Aggressive Fund
DIADEXUS, INC.                         (Investor)

By:                                    By: /s/ Frederick C. Quirsfeld
    ------------------------------         -------------------------------------
                                       Name:   Frederick C. Quirsfeld
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:     Vice President
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   25

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

                                       AXP Variable Portfolio, Inc. -- AXP
                                       Strategy Aggressive Fund
DIADEXUS, INC.                         (Investor)

By:                                    By: /s/ Frederick C. Quirsfeld
    ------------------------------         -------------------------------------

                                       Name:   Frederick C. Quirsfeld
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:  Vice President
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   26

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

                                       BAVP, L.P.
                                       By:     BA Venture Partners VI, LLC
DIADEXUS, INC.                                 its General Partner
                                       -----------------------------------------
                                       (Investor)

By:                                    By: /s/ Louis C. Bock
    ------------------------------         -------------------------------------
                                       Name:   Louis C. Bock
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:     Managing Member
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   27

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

                                       By:     Moore Global Investments, Ltd.

DIADEXUS, INC.                         By:     Moore Capital Management, Inc.

By:                                    By: /s/ Savvas Savvinidis
    ------------------------------         -------------------------------------
                                       Name:   Savvas Savvinidis
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:  Trading Manager
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   28

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         -----------------------------------------
                                       (Investor)

By:                                    By:
    ------------------------------         -------------------------------------
                                       Name:
                                             -----------------------------------
Address:                                          (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:                              REMINGTON INVESTMENT STRATEGIES, L.P.

                                       By:   Moore Capital Advisors, L.L.C.
                                             General Partner

----------------------------------
SmithKline Beecham Corporation

                                         /s/ Savvas Savvinidis
                                       -----------------------------------------
                                       Savvas Savvinidis
Address:
                                       Title:     Director of Operations
                                              ----------------------------------
Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   29

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

                                       By:  Moore Global Fixed Income Fund, Ltd.

DIADEXUS, INC.                         By:  Moore Capital Management, Inc.

By:                                    By:  /s/ Savvas Savvinidis
    ------------------------------         -------------------------------------
                                       Name:    Savvas Savvinidis
                                             -----------------------------------
Address:                                        (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:   Director of Operations
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   30

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                             Brookside Capital Partners Fund, L.P.
                                       -----------------------------------------
                                       (Investor)

By:                                    By: /s/ Ed Brakeman
    ------------------------------         -------------------------------------
                                       Name:      Ed Brakeman
                                             -----------------------------------
Address:                                          (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:     Managing Director
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   31

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

                                       RHO Management Trust I
                                       By:     Rho Management Company, Inc.
DIADEXUS, INC.                                 Investment Advisor

By:                                    By:     /s/ Mark Leschley
    ------------------------------         -------------------------------------
                                       Name:   Mark Leschley
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:  Managing Director
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   32

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                             Bay Star Capital, L.P.
                                       -----------------------------------------
                                       (Investor)

By:                                    By:    /s/ Michael A. Roth
    ------------------------------         -------------------------------------
                                       Name:  Michael A. Roth
                                             -----------------------------------
Address:                                      (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title: Member - Investment Manager
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   33

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                             Bay Star Capital, LTD
                                       -----------------------------------------
                                       (Investor)

By:                                    By: /s/ Michael A. Roth
    ------------------------------         -------------------------------------
                                       Name:      Michael A. Roth
                                             -----------------------------------
Address:                                          (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:     Member - Investment Manager
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   34

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         ESSEX PRIVATE PLACEMENT FUND III A
                                       Limited Partnership

By:                                    By:   Essex Investment Management
    ------------------------------           Company, LLC its General Partner

                                       By:      /s/ Susan P. Stickells
                                           -------------------------------------

                                       Name:    Susan P. Stickells
                                             -----------------------------------
Address:                                        (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:   Principal
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   35

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         ESSEX PRIVATE PLACEMENT FUND III B
                                       Limited Partnership

By:                                    By:   Essex Investment Management
    ------------------------------           Company, LLC its General Partner

                                       By:      /s/ Susan P. Stickells
                                           -------------------------------------

                                       Name:    Susan P. Stickells
                                             -----------------------------------
Address:                                        (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:   Principal
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   36

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         THE KAUFMANN FUND, INC.
                                       (Investor)

By:                                    By:     /s/ Lawrence Auriana
    ------------------------------         -------------------------------------
                                       Name:   Lawrence Auriana
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:  Chairman
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   37

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         FOUR PARTNERS
                                       (Investor)

By:                                    By:     /s/ Tom Tisch
    ------------------------------         -------------------------------------
                                       Name:   Tom Tisch
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:  Trustee
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   38

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         BAKER / TISCH INVESTMENT
                                       (Investor)

By:                                    By:    /s/ Julian Baker
    ------------------------------         -------------------------------------

                                       Name:  Julian Baker
                                             -----------------------------------
Address:                                      (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title: Managing Member of Managing Member
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   39

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                          FBB ASSOCIATES
                                        (Investor)

By:                                     By:     /s/ Julian Baker
    ------------------------------         -------------------------------------
                                        Name:   Julian Baker
                                              ----------------------------------
Address:                                        (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                        Title:  Partner
                                               ---------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   40

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

                                       BRITISH AIRWAYS PENSION
DIADEXUS, INC.                         TRUSTEES
                                       (Investor)

By:                                    By: /s/ John Birch /s/ Linda Jackson
    ------------------------------         -------------------------------------
                                       Name:   John Birch    Linda Jackson
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:  Authorized Signatories
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   41

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         MCP GLOBAL CORP. LTD.
                                       (Investor)

By:                                    By:     /s/ Mai N. Pogue
    ------------------------------         -------------------------------------
                                       Name:   Mai N. Pogue
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:  Director
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   42

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         EAG ENTERPRISES LTD.
                                       (Investor)

By:                                    By:     /s/ Mai N. Pogue
    ------------------------------         -------------------------------------
                                       Name:   Mai N. Pogue
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:  Investment Manager
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   43

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         CLOSEFIRE LTD.
                                       (Investor)

By:                                    By:     /s/ Mai N. Pogue
    ------------------------------         -------------------------------------
                                       Name:   Mai N. Pogue
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:  Investment Manager
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   44

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         NILOUFAR PAHLAVI
                                       (Investor)

By:                                    By:     /s/ Mai N. Pogue
    ------------------------------         -------------------------------------
                                       Name:   Mai N. Pogue
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:  Investment Manager
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   45

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         CODITEC INTL LTD - LION
                                       (Investor)

By:                                    By:     /s/ Mai N. Pogue
    ------------------------------         -------------------------------------
                                       Name:   Mai N. Pogue
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:  Investment Manager
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   46

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         LOMBARD ODIER & CIE
                                       (Investor)

By:                                    By:     /s/ C. Gokok   /s/ A. Meyer
    ------------------------------         -------------------------------------
                                       Name:   Carmela Gokok / Alexandre Meyer
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:  Assistant Vice Presidents
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   47

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         NARRAGANSETT I LP
                                       (Investor)

By:                                    By:     /s/ Joseph L. Dowling III
    ------------------------------         -------------------------------------
                                       Name:   Joseph L. Dowling III
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:  Managing Member
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   48

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         NARRAGANSETT OFFSHORE, LTD.
                                       (Investor)

By:                                    By:     /s/ Joseph L. Dowling III
    ------------------------------         -------------------------------------
                                       Name:   Joseph L. Dowling III
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:  Managing Member
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   49

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         BLUE RIDGE LIMITED PARTNERSHIP
                                       (Investor)

By:                                    By:     /s/ Richard Bello
    ------------------------------         -------------------------------------
                                       Name:   Richard Bello
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:  MD
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   50

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         BLUE RIDGE PRIVATE EQUITY FUND
                                       (Investor)

By:                                    By:     /s/ Richard Bello
    ------------------------------         -------------------------------------
                                       Name:   Richard Bello
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:  MD
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   51

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         -----------------------------------------
                                       (Investor)

By:                                    By:
    ------------------------------         -------------------------------------
                                       Name:
                                             -----------------------------------
Address:                                          (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:                              BIOTECHNOLOGY VALUE FUND, L.P.
                                       By:        BVF PARTNERS L.P.,
                                                  its General Partner

----------------------------------     By:        BVF, INC., its General Partner
SmithKline Beecham Corporation
                                       By:        /s/ Mark N. Lampert
                                           -------------------------------------
                                                  President
Address:

                                       BIOTECHNOLOGY VALUE FUND II, L.P.
                                       By:        BVF PARTNERS L.P.,
Fax:                                              its General Partner

                                       By:        BVF, INC., its General Partner
----------------------------------
Incyte Pharmaceuticals, Inc.           By:        /s/ Mark N. Lampert
                                           -------------------------------------
                                                  President

Address:                               INVESTMENT 10 L.L.C.
                                       By:        BVF PARTNERS, L.P.,
Fax:                                              Its Investment Advisor

                                       By:        BVF, INC., its General Partner

                                       By:        /s/ Mark N. Lampert
                                           -------------------------------------
                                                  President

<PAGE>   52

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         ADMIRALS, L.P.
                                       (Investor)

By:                                    By:     /s/ Thomas E. Fernandez
    ------------------------------         -------------------------------------
                                       Name:   Thomas E. Fernandez
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:  COO
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   53

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                                 /s/ David Gerstenhaber
                                       -----------------------------------------
                                       (Investor)

By:                                    By:     David Gerstenhaber
    ------------------------------         -------------------------------------
                                       Name:   Quota Rabbico II, Ltd.
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:  President
                                             -----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   54

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                                 /s/ David Gerstenhaber
                                       -----------------------------------------
                                       (Investor)

By:                                    By:     David Gerstenhaber
    ------------------------------         -------------------------------------
                                       Name:   Argonaut Partnership, L.P.
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:  President
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   55

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                                 /s/ David Gerstenhaber
                                       -----------------------------------------
                                       (Investor)

By:                                    By:     David Gerstenhaber
    ------------------------------         -------------------------------------
                                       Name:   Argonaut Investment Fund, Ltd.
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:  President
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   56

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                                 /s/ David Gerstenhaber
                                       -----------------------------------------
                                       (Investor)

By:                                    By:
    ------------------------------         -------------------------------------
                                       Name:   David Gerstenhaber
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   57

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         THE HARE INVESTMENT FUND, LP
                                       (Investor)

By:                                    By:     /s/ William J. Haggerty
    ------------------------------         -------------------------------------
                                       Name:   William J. Haggerty
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:  Chief Operating Officer
                                              ----------------------------------
Fax:                                           Aesop Capital Partners
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   58

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         ACP INVESTMENTS, LP
                                       (Investor)

By:                                    By:     /s/ William J. Haggerty
    ------------------------------         -------------------------------------
                                       Name:   William J. Haggerty
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:  Chief Operating Officer
                                              ----------------------------------
Fax:                                           Aesop Capital Partners
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   59

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         ZEKE, L.P.
                                       (Investor)

By:                                    By:     /s/ Edward P. Antonian
    ------------------------------         -------------------------------------
                                       Name:   Edward P. Antonian
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:  General Partner
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   60

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         SIA PARTNERSHIP XVI
                                       (Investor)

By:                                    By:     /s/ Eugene C. Sit
    ------------------------------         -------------------------------------
                                       Name:   Eugene C. Sit
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:  General Partner, SIA Partnership
                                              ----------------------------------
                                               XVI
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   61

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         TREG HOLDINGS S.A.
                                       (Investor)

By:                                    By:     /s/ Dr. Gian Germano Giuliani
    ------------------------------         -------------------------------------
                                       Name:   Dr. Gian Germano Giuliani
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:  Chief Executive Officer
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   62

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         STEVEN S. HELMS
                                       (Investor)

By:                                    By:     /s/ Steven S. Helms
    ------------------------------         -------------------------------------
                                       Name:   Steven S. Helms
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   63

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         ACTIVE SITE PARTNERS, L.P.
                                       (Investor)

By:                                    By:     /s/ Jeffrey C. Edman
    ------------------------------         -------------------------------------
                                       Name:   Jeffrey C. Edman
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:  General Partner
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   64

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         RICHARD M. DRURY
                                       (Investor)

By:                                    By:     /s/ Richard M. Drury
    ------------------------------         -------------------------------------
                                       Name:   Richard M. Drury
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   65

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         WHITTIER VENTURES L.L.C.
                                       (Investor)

By:                                    By:     /s/ David A. Dahl
    ------------------------------         -------------------------------------
                                       Name:   David A. Dahl
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:  President
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   66

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         J. F. SHEA CO., INC. AS NOMINEE 2000-60
                                       (Investor)

By:                                    By:     /s/ Edmund H. Shea, Jr.
    ------------------------------         -------------------------------------
                                       Name:   Edmund H. Shea, Jr.
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:  Vice President
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   67

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         -----------------------------------------
                                       (Investor)

By:                                    By:     /s/ Craig R. Smith, M.D.
    ------------------------------         -------------------------------------
                                       Name:   Craig R. Smith, M.D.
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   68

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         MERIKEN NOMINEES LTD
                                       (Investor)

By:                                    By:     Its Director Atco Nominees Ltd.
    ------------------------------         -------------------------------------
                                       By:     Authorized Signatory
                                           -------------------------------------
                                       Name:
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   69

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         R. WARNKING
                                       (Investor)

By:                                    By:     /s/ Reinhard Warnking
    ------------------------------         -------------------------------------
                                       Name:   Reinhard Warnking
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   70

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         JAMES C. KELLY
                                       (Investor)

By:                                    By:     /s/ James C. Kelly
    ------------------------------         -------------------------------------
                                       Name:   James C. Kelly
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:  Senior V.P. and C.F.O.
                                              ----------------------------------
Fax:                                          c/o Mutual Risk Management Ltd.
408-496-5777                                  44 Church Street
                                              Hamilton, H.M. HX, Bermuda

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   71

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         MRM LIFE LTD.
                                       (Investor)

By:                                    By:     /s/ Iain Brackstone
    ------------------------------         -------------------------------------
                                       Name:   Iain Brackstone
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:  Vice President
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   72

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         SIOBAIN MELANIE MARIE PREW
                                       (Investor)

By:                                    By:     /s/ Siobain Melanie Marie Prew
    ------------------------------         -------------------------------------
                                       Name:   Siobain Melanie Marie Prew
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:  MRS
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   73

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         ANITA N. DEMAS
                                       (Investor)

By:                                    By:     /s/ Anita N. Demas
    ------------------------------         -------------------------------------
                                       Name:   Anita N. Demas
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   74

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         THOMAS L. SABEL
                                       (Investor)

By:                                    By:     /s/ Thomas L. Sabel
    ------------------------------         -------------------------------------
                                       Name:   Thomas L. Sabel
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   75

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         LOUIS LANGE
                                       (Investor)

By:                                    By:     /s/ Louis Lange
    ------------------------------         -------------------------------------
                                       Name:   Louis Lange
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   76

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         DANIEL P. STAUDER
                                       (Investor)

By:                                    By:     /s/ Daniel P. Stauder
    ------------------------------         -------------------------------------
                                       Name:   Daniel P. Stauder
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   77

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         PAUL LANDINI
                                       (Investor)

By:                                    By:     /s/ Paul Landini
    ------------------------------         -------------------------------------
                                       Name:   Paul Landini
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:  Senior VP
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   78

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         JAMES S. GINSBURG
                                       (Investor)

By:                                    By:     /s/ James S. Ginsburg
    ------------------------------         -------------------------------------
                                       Name:   James S. Ginsburg
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   79

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         JEFFREY C. HAMMES
                                       (Investor)

By:                                    By:     /s/ Jeffrey C. Hammes
    ------------------------------         -------------------------------------
                                       Name:   Jeffrey C. Hammes
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   80

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         THOMAS C. DORN
                                       (Investor)

By:                                    By:     /s/ Thomas C. Dorn
    ------------------------------         -------------------------------------
                                       Name:   Thomas C. Dorn
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   81

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         JAMES N. NOWACKI
                                       (Investor)

By:                                    By:     /s/ James N. Nowacki
    ------------------------------         -------------------------------------
                                       Name:   James N. Nowacki
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   82

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         MARINA BOZILENKO
                                       (Investor)

By:                                    By:     /s/ Marina Bozilenko
    ------------------------------         -------------------------------------
                                       Name:   Marina Bozilenko
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   83

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         ROBERT J. TOTH, JR.
                                       (Investor)

By:                                    By:     /s/ Robert J. Toth, Jr.
    ------------------------------         -------------------------------------
                                       Name:   Robert J. Toth, Jr.
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   84

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.
                                       (Investor)

By:                                    By:     /s/ Kay L. Gurtin
    ------------------------------         -------------------------------------
                                       Name:   Kay L. Gurtin
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   85

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         LAURA P. COPLAN
                                       (Investor)

By:                                    By:     /s/ Laura P. Coplan
    ------------------------------         -------------------------------------
                                       Name:   Laura P. Coplan
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   86

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         JAMES H.M. SPRAYREGEN
                                       (Investor)

By:                                    By:     /s/ James H.M. Sprayregen
    ------------------------------         -------------------------------------
                                       Name:   James H.M. Sprayregen
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   87

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         LATHAM & WATKINS
                                       (Investor)

By:                                    By:     /s/ Robert A. Koenig
    ------------------------------         -------------------------------------
                                       Name:   Robert A. Koenig
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:  Partner
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   88

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         MICHAEL W. HALL
                                       (Investor)

By:                                    By:     /s/ Michael W. Hall
    ------------------------------         -------------------------------------
                                       Name:   Michael W. Hall
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   89

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         ROBERT A. KOENIG
                                       (Investor)

By:                                    By:     /s/ Robert A. Koenig
    ------------------------------         -------------------------------------
                                       Name:
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   90

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         STEPHEN B. RICHARDS
                                       (Investor)

By:                                    By:     /s/ Stephen B. Richards
    ------------------------------         -------------------------------------
                                       Name:   Stephen B. Richards
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   91

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         JEFFREY L. MILLER
                                       (Investor)

By:                                    By:     /s/ Jeffrey L. Miller
    ------------------------------         -------------------------------------
                                       Name:   Jeffrey L. Miller
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   92

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.
                                       -----------------------------------------
                                       (Investor)

By:                                    By: /s/ Frederick J. Cluskey
    ------------------------------         -------------------------------------
                                       Name:   Frederick J. Cluskey
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:
                                              ----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

<PAGE>   93

        The parties have executed this Investors' Rights Agreement as of the
date first above written.

COMPANY:                               INVESTORS:

DIADEXUS, INC.                         SMITHKLINE BEECHAM CORPORATION
                                       (Investor)

By:                                    By:     /s/ Donald F. Parman
    ------------------------------         -------------------------------------
                                       Name:   Donald F. Parman
                                             -----------------------------------
Address:                                       (print)
3303 Octavius Drive
Santa Clara, CA 95054
                                       Title:  Secretary
                                             -----------------------------------
Fax:
408-496-5777

FOUNDERS:

----------------------------------
SmithKline Beecham Corporation

Address:

Fax:

----------------------------------
Incyte Pharmaceuticals, Inc.

Address:

Fax:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00018-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00018-of-00352.parquet"}]]